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ABSTRACT 
 
Patricia Pozella: Strategies for Increasing EGFR Mutation Testing of Patients with  
Non-Small Cell Lung Cancer 
(Under the direction of Edward Brooks and Suzanne Hobbs) 
 
 Background: More than 228,000 people are diagnosed with non-small cell lung cancer 
(NSCLC) each year in the United States, and most die within a year.  Newer targeted medications, 
including erlotinib and afatinib, work at a molecular level to produce profound and sustained benefit 
for a small percentage of patients.  Specific genetic mutations, including changes in the EGFR gene, 
identify individuals more likely to respond to targeted therapies.  Published literature shows that using 
results of EGFR testing to guide treatment decisions results in significantly better treatment 
outcomes.  Mutation testing is done routinely at most academic medical centers and cancer centers; 
however, use in community settings is highly variable and significantly less common.  Reasons for 
the disparity in testing rates are unknown.   
 Methods: Twenty-three key informant interviews were conducted with community 
oncologists practicing in southeastern states to identify facilitators and barriers to use of EGFR testing 
in community settings.   
 Results: Two characteristics predicted an increased likelihood of EGFR testing of patients 
with advanced or metastatic NSCLC, including less time passed since completion of oncology 
training, and treating a higher number of patients with NSCLC each month.   The most frequently 
mentioned facilitator was clinical literature and treatment guidelines.  The most commonly cited 
barriers to testing included patient-related reasons, such as patient health and unwillingness to be 
tested, and oncologist-specific reasons.  Eight-seven percent of oncologists who reported testing some  
  
iv 
or none of their patients expressed confidence in their abilities to make optimal treatment decisions 
based on clinical judgment and experience instead of relying on test results.   
 Conclusions: This study suggests there is much work to be done to increase use of EGFR 
testing by oncologists practicing in community settings.  The first step involves convening a task 
force with representatives from a variety of constituencies that will develop and implement an 
integrated communications plan focusing on three audiences--community oncologists, other 
healthcare professionals, and patients, families, caregivers, and advocates located in North Carolina.  
Each tactic will be measured and evaluated after completion based on pre-established objectives.  
Regional and national expansion of the communications plan will be based on the results of the North 
Carolina pilot.  
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CHAPTER 1 
Overview 
Prevention and treatment of lung cancer are major public health issues.  Over 228,000 people 
are diagnosed in the U.S. with non-small cell lung cancer (NSCLC) each year; most are diagnosed 
with late stage incurable cancer and will die within one year (American Cancer Society, 2013).  
Beyond the cost in human lives, lung cancer treatments account for almost 10% of the billions spent 
each year on cancer care (ASCO, 2012; Mariotto, 2011) with most of the money being spent during 
patients’ last year of life.   
There are two main treatment options for these individuals—traditional chemotherapy and 
newer targeted oral medications.  There are obvious advantages to taking an oral medication instead 
of receiving intravenous infusions; however, response rates to oral therapies used in a general 
population of patients being treated for advanced or metastatic NSCLC are very low (Shepard F. A., 
2005).  Researchers have discovered the presence of specific mutations in the epidermal growth factor 
receptor (EGFR) gene in a tumor sample predict treatment response to certain oral medications 
(Eberhard, 2008; John, 2009; Levenson, 2008; Maemondo, 2010; Mok, 2009; Riely, 2006).  
Molecular tests used to identify the presence of EGFR mutations are widely available and moderately 
priced (Printz, 2010).   
For individuals who have an EGFR mutation, the response to an oral therapy can be dramatic 
and prolonged; however, these same people tend to do poorly when treated with traditional 
chemotherapy  (Gandara, 2010; Gridelli, 2008; Lennes, 2011; Printz, 2010).  The opposite is true for 
patients without an EGFR mutation.  Selecting the wrong treatment approach has significant 
consequences in terms of morbidity, mortality, and cost.  
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The only way to know for sure if a patient’s tumor harbors the EGFR mutation is to test for it 
(Cataldo, 2011; Gazdar A. , 2010; Lennes, 2011; Maione, 2010; Printz, 2010; Shepard F. A., 2011; 
West J. H., 2010).  Despite overwhelming evidence that pretreatment EGFR testing is the best way to 
determine the most appropriate treatment option for individual patients with NSCLC, many 
oncologists do not test patients’ tumors for EGFR mutations before prescribing treatment (Alt, 2011).  
Little is known about why.  Lung cancer experts often speculate about the reasons, but there are no 
published data confirming their suspicions.   
This research effort seeks to enhance the understanding of the factors oncologists consider 
when deciding whether to test tumor samples for EGFR mutations before prescribing treatment for 
patients with advanced or metastatic NSCLC.  The research findings, along with insights gained from 
a review of relevant literature will be used to develop a plan for increasing the use of EGFR testing by 
oncologists.    
Background 
Cancer is a significant public health burden from both the prevention and treatment 
perspectives; over 1.6 million Americans are expected to be diagnosed with some form of cancer in 
2013 (American Cancer Society, 2013).  It is the second leading cause of death in the United States, 
behind cardiovascular disease, accounting for slightly more than one in four deaths annually 
(American Cancer Society, 2013; Janne, 2006; Jemal, 2010).  Each year over 228,000, individuals in 
the U.S. receive the devastating news they have lung cancer.  
More than 160,000 individuals succumb to lung cancer each year, making it the leading cause 
of cancer deaths in the U.S.  Approximately 85% of people diagnosed with lung cancer die within 
five years of diagnosis  primarily due to being diagnosed at an advanced stage (IIIB and IV) when the 
cancer is no longer localized to a single area and is incurable (Altecruse, 2010; American Cancer 
Society, 2013; Maione, 2010).  Individuals diagnosed at an advanced stage usually have a very short 
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lifespan (Gazdar A. F., 2009; Perez-Soler, 2009; West, 2010).  Median survival is 8 to 10 months at 
diagnosis even with aggressive treatment (American Cancer Society, 2013; Dancey, 2007; Levenson, 
2008; Sequist L. B., 2007).  The median time to cancer progression averages three to five months 
after initial treatment (Shepard F. A., 2005; Shepard F. A., 2005), and only 30 to 40% of patients are 
alive one year after diagnosis (Dowell, 2005).   
 The good news is there has been a great deal of progress made in recent years in the 
understanding of the underlying genetics of lung cancer (Amler, 2005; John, 2009; Murdoch, 2008; 
Printz, 2010; Sequist L. V., 2008), which has lead to the development of a small number of targeted 
drug therapies that prolong survival in a subset of patients diagnosed with advanced or metastatic 
NSCLC.  In November 2004, the US Food and Drug Administration (FDA) approved one of the 
targeted medications, erlotinib (brand name Tarceva®), for use in patients with advanced NSCLC 
whose cancer has continued to progress after at least one prior traditional chemotherapy regimen 
(Genentech Inc., 2012; Huff, 2010).   
As is the case with most new cancer therapies, the approval of erlotinib was trumpeted by 
media outlets, which generated significant enthusiam and interest among patients and the medical 
community (Arp, 2005; Beil, 2009; Calfee, 2006; Langreth, 2010; Pho, 2011; Tsao A. , 2001).  Lester 
Crawford, MD, the acting FDA Commissioner was quoted in press coverage as saying, “’with the 
approval of Tarceva, thousands of patients with lung cancer will not only have access to another 
treatment option, but one that extends life’” (U.S. Food and Drug Administration, 2004).  Indeed, a 
small percent of patients with advanced NSCLC have a dramatic and prolonged response to erlotinib 
(Shepard F. A., 2005; Shepard F. A., 2005); unfortunately, the vast majority of patients do not benefit 
from the medication, although media reports may suggest otherwise (Arp, 2005; Beil, 2009; Calfee, 
2006; Langreth, 2010; Pho, 2011; Tsao A. , 2001).   
The FDA approval of erlotinib was based on a single randomized, double-blind, placebo 
controlled study involving 731 patients (U.S. Food and Drug Administration, 2004).  The response 
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rate in the group treated with erlotinib was 8.9% compared with less than 1% in the group treated 
with placebo.  Overall survival for patients treated with erlotinib was two months longer than those 
treated with placebo (6.7 months vs. 4.7 months respectively), which is a statistically significant 
difference.  
Clearly, the medication does not work for all patients, so clinicians are left with the task of 
attempting to prospectively identify individuals who are likely to be among the small percentage of 
people who will respond to the medication.  Researchers have observed in clinical trials of erlotinib 
and a similar drug, gefitinib (brand name Iressa™), used in a general population of people with 
advanced or metastatic NSCLC that individuals who responded to medication tended to share certain 
easily identifiable characteristics (Giaccone G. , 2005; Lynch, 2004; Paez, 2004; Pao W. M., 2004; 
Shepard F. A., 2005; Shepard F. A., 2005).  Unfortunately, these traits—alone or in combination--are 
not infallibly predictive of response to erlotinib and the absence of these characteristics is not a 
reliable indicator an individual will not respond to treatment (Balko, 2006; Nierendgarten, 2010; 
Perez-Soler, 2009); assuming either can lead to inappropriate over or under prescribing of erlotinib 
If personal observations and clinical experience are not enough to accurately guide a 
physician’s treatment decisions how can we improve the odds of selecting good candidates for 
erlotinib therapy (Printz, 2010)?  As mentioned above, the presence of specific identifiable genetic 
mutations (changes) in the EGFR gene found in lung tumor tissue predict a patient’s likelihood of 
benefitting from treatment with erlotinib (Eberhard, 2008; John, 2009; Levenson, 2008; Maemondo, 
2010; Mok, 2009; Riely, 2006).   
The EGFR gene signals cells to grow and divide; genetic abnormalities in the EGFR gene 
result in uncontrolled cell growth and proliferation leading to the formation of malignant tumors 
(Pennell, 2010).  Erlotinib works by interfering with this processs (Bonomi, 2007; Johnston, 2006; 
Robinson, 2006; Shepard F. A., 2005).  
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Only 10 to 20% of patients in the U.S. with adenocarcinoma-type advanced or metastatic 
NSCLC tumors harbor genetic mutations in specific regions of the EGFR gene known to be  
associated with positive clinical response to erlotinib (Amler, 2005; Giaccone G. a., 2005; Keedy V. 
L., 2011; Lynch, 2004; Paez, 2004; Pao W. L., 2005; Tsao M. S.-R., 2005).  However, not all  
patients with these mutations will benefit from the medication (Ciardiello, 2008; Giaccone G. a., 
2005; Reck, 2010; Sequist L. V., 2008).   
EGFR mutations can be detected using commercially available tests; the tests mitigate the 
need to rely solely on a physician’s observations and clinical judgment based on phenotypic 
(observed) patient, tumor and demographic characteristics (Pennell, 2010).  In this paper, the terms 
EGFR molecular testing, EGFR molecular mutation testing, EGFR mutation testing, EGFR testing, 
mutation testing, and biomarker testing are used interchangeably. 
The FDA does not require physicians to perform an EGFR test before prescribing erlotinib 
(Genentech and (osi) oncology, 2011); physicians are free to prescribe it for any patient with lung 
cancer without restriction.  But there are clear advantages to prospectively identifying patients who 
are more likely to respond to erlotinib, as well as those who lack the EGFR mutation and are unlikely 
to respond (Cataldo, 2011; Gazdar A. , 2010; Lennes, 2011; Maione, 2010; Printz, 2010; Shepard F. 
A., 2011; West J. H., 2010).   
What are the implications of prescribing erlotinib for patients who are unlikely to respond to 
treatment?   There are many, ranging from the costs associated with purchasing ineffective 
medication to unnecessary exposure to adverse drug effects to premature death.  There are also 
significant risks associated with not treating patients who are likely to respond to erlotinib.  People 
who benefit from erlotinib treatment often have a sustained period of progression free survival that is 
unlikely to be achieved with traditional chemotherapy.  There is a “significant penalty in terms of 
overall survival” when patients with the EGFR mutation are treated with chemotherapy rather than 
erlotinib (West J. H., 2010).  The opposite is true for people who do not have an EGFR mutation;  
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they have little chance of responding to erlotinib, which leaves chemotherapy as the only viable 
treatment option except for a very small number of patients who harbor other genetic mutations, 
which make them more likely to respond to other targeted therapies.   
Although molecular tests that can identify specific mutations in the EGFR gene have been 
available since 2005, a recent study conducted by Julie Lynch, PhD, confirms EGFR mutation testing 
is vastly underused by oncologists practicing in the U.S. (Alt, 2011; Lynch J. A., 2013; Lynch J. A., 
2013).  A more recent publication suggests that EGFR testing rates may have improved slightly since 
the release of the Lynch study, but are far from optimal (Chustecka, 2013).  Unfortunately, little is 
known about how oncologists decide what patients to test for EGFR mutations; experts have 
expressed opinions, but there are no published data available on the subject.  The purpose of this 
dissertation is to begin identifying and understanding the factors influencing oncologists’ decisions 
about using pretreatment EGFR tests.  The results of the research outlined in chapter four along with 
the knowledge and insights gained during the literature review will be used to develop a plan for 
increasing pretreatment EGFR testing of patients with advanced or metastatic NSCLC.    
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CHAPTER 2 - LITERATURE REVIEW 
The literature review conducted for this dissertation is very detailed and lengthy.  Rather than 
including the complete literature review in this chapter of the manuscript, it has been moved to 
Appendix A to facilitate readability.  Instead, this chapter contains a brief overview of the contents of 
Appendix A, which contains two parts and a summary.  Part one has a detailed review of the 
epidemiology and etiology of lung cancer, as well as treatment options.  It also contains a summary of 
the role tumor genetics play in treatment selection for patients with NSCLC, the availability of 
molecular tests that identify EGFR mutations that predict treatment response, and the low rate of use 
of EGFR tests by oncologists practicing in the U.S.  Part two of chapter two includes a review of 
factors that influence and motivate physicians’ behavior.   
Part One: Understanding Non-Small Cell Lung Cancer and Treatments 
The effectiveness of traditional chemotherapy reached a plateau in the 1970s, leaving little 
hope for extended survival among those diagnosed with advanced or metastatic NSCLC (Breathnach, 
2001; Maione, 2010).  However, the tide began turning in the past decade with the launch of a small 
number of new oral targeted medications, including erlotinib, developed as a result of research into 
the genetic basis of lung cancer (Amler, 2005; John, 2009; Murdoch, 2008; Printz, 2010; Sequist L. 
V., 2008).  The majority of patients who respond to erlotinib have a dramatic response resulting in 
remission that is sustained over a period of two to five years (Shepard F. A., 2005; Shepard F. A., 
2005); unfortunately, the response rate in the general population of people treated for advanced or 
metastatic NSCLC is below 10%. 
It is challenging for oncologists to correctly identify the individuals likely to respond to 
erlotinib.  A number of early clinical studies involving the drug revealed patients with certain 
characteristics, including never smoking, female gender, Asian race, and tumors with adenocarcinoma  
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histology tended to have better response rates and treatment outcomes than individuals who lack these 
traits (Giaccone G. , 2005; Lynch, 2004; Paez, 2004; Pao W. M., 2004; Shepard F. A., 2005; Shepard 
F. A., 2005).  As a result, these characteristics have become an informal guide for oncologists who 
are making treatment decisions for patients with NSCLC.  While this approach is more accurate than 
relying on a physician’s “gut feel”, it often leads to inappropriate prescribing of erlotinib (Balko, 
2006; Nierendgarten, 2010; Perez-Soler, 2009).  Studies show less than one quarter of patients with 
advanced or metastatic NSCLC, including those with the characteristics listed above, have a mutation 
in the EGFR gene predictive of a positive response to erlotinib (Amler, 2005; Giaccone G. a., 2005; 
Keedy V. L., 2011; Lynch, 2004; Paez, 2004; Pao W. L., 2005; Tsao M. S.-R., 2005); of those, 
approximately half will respond to erlotinib (Printz, 2010).  
Why is it important to select the right course of therapy initally when patients can be 
switched easily to another treatment regimen?  Researchers predicted early on that response rates 
would be similar regardless of whether patients started on chemotherapy or erlotinib and then 
switched to the other when their cancer progressed (Brooks, 2012; Gandara, 2010; Gridelli C. B., 
2008; West J. H., 2010; West J. H., 2010; West J. H., 2010).  However, results of recent studies 
indicate the order of treatment—standard chemotherapy given first followed erlotinib or vice versa 
matters greatly with respect to treatment outcomes.  People who have an EGFR gene mutation fare 
significantly better when treated with erlotinib first instead of chemotherapy; the opposite is true for 
people without a mutation.  For example, patients without an EGFR mutation who received 
chemotherapy first had a 28% response rate vs. ten percent in those who received it second-line after 
failing to respond to erlotinib.  More than half of patients started on erlotinib did not live long enough 
to be switched to chemotherapy.  
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(Brooks, 2012; Gandara, 2010; Lennes, 2011) 
 
Patient with 
advanced or 
metastatic 
NSCLC 
Perform an 
EGFR test 
EGFR +  
begin erlotinib 
EGFR-  
begin 
chemotherapy 
No EGFR test 
Begin 
chemotherapy 
 
Figure 1 - Survival Statistics for Advanced or Metastatic NSCLC 
 
 
 
Figure 2 - Treatment Paradigm for Patients with Advanced or Metastatic NSCLC 
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(Brooks, 2012; Gandara, 2010; Lennes, 2011; Mok, 2009; Rosell, 2012) 
Although a growing body of published data confirms the benefits of prospective EGFR 
mutation testing of tumor tissue taken from patients with advanced or metastatic NSCLC, many 
oncologists continue treating every patient the same, as if NSCLC is a homogeneous disease (Gridelli 
C. B., 2008).  Oncologists who understand individual patients may respond differently to erlotinib 
most often use the characteristics listed above to identify patients they think are more likely to 
respond instead of ordering EGFR tests to confirm their suspicions. 
According to a study presented by Julie Lynch, PhD, at the 2011 American Association for 
Cancer Research (AARC) Cancer Disparities Conference, EGFR mutation testing is vastly underused 
by oncologists in the US even though it is a significantly more reliable predictor of treatment 
response than treatment decisions made on the basis of clinical judgment or observations alone (Alt, 
2011; Lynch J. A., 2013; Shepard F. A., 2011).  A recent article quoting Marc Ladanyi, MD, a lung 
cancer specialist practicing at Memorial Sloan Kettering Cancer Center, suggests testing rates may 
have improved somewhat in major cancer centers since the release of the Lynch data, but tests are 
still being significantly underutilized by oncologists practicing in community settings (Chustecka, 
2013).     
EGFR Test 
EGFR+  
(10% to 20% of 
patients) 
Erlotinib 50%-85% 
Chemotherapy 18% 
EGFR-  
(80% to 90% of 
patients) 
Erlotinib 1.1% 
Chemotherapy 28 - 35% 
Test result 
First-line  
treatment 
Treatment 
response rate 
Figure 3 - Treatment Response Rates by EGFR Mutation Status 
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On paper, the choice seems clear, but obviously it is not or use of EGFR testing would be 
more widespread.  There are obviously barriers to adoption of molecular testing, but there are no 
published data providing insights into the reasons why many oncologists choose not to order EGFR 
tests before prescribing treatment for their patients with NSCLC.    
Part Two: Influencing Physicians' Clinical Behaviors and Decisions   
Motivating physicians to change their clinical practice behaviors is no easy task (Grimshaw J. 
M., 2004; Lomas, 1989; Osarogiagbon, 2011; Roila, 2004; Satterlee, 2008; Wong R. K., 2012).  
There are a myriad of factors influencing change; some are positive and others are negative.  Several 
factors were explored in part two of chapter two (see Appendix A); they are listed in the table below 
(Cochrane Effective Practice and Organisation of Care Group, 2012; Edwards, 2009; Flodgren G. E., 
2011; Flodgren G. P., 2011; Freemantle, 1995; Giguère, 2012; Ivers, N., 2012; O’Brien, 2008; 
Pantoja, 2009; Satterlee, 2008).   
Table 1 - Factors Influencing Physicians' Clinical Behavior 
 
Facilitators of change Barriers to change 
 Federal legislation and regulations 
 Institute of Medicine reports 
 Lung Cancer Mutation Consortium 
and the Biomarkers Consortium 
 Patient advocacy organizations 
 Health care professional associations 
 Payers/Managed care organizations 
(MCOs) 
 Clinical practice guidelines 
 
 Federal legislation and regulations 
 Payers/MCOs 
 Lack of motivation or time/clinical inertia 
 Information and work overload 
 Lack of knowledge or training in genetics 
 Lack of buy-in for need to change 
 Disagreement with proposed changes 
 Perceived threat to personal autonomy 
 Aversion to “cookbook” medicine 
 Fear of genetic discrimination against patients by 
employers and insurers 
 
There is no “magic bullet” for developing successful interventions aimed at motivating physicians 
to change their approach to diagnosing and treating specific diseases (Oxman, 1995).  Developing formal 
clinical practice guidelines is an important first step in creating a path and rationale for change (Cabana 
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M. D., 1999; Wong R. K., 2012).  However, motivating physicians to follow established guidelines 
remains a significant challenge (Aspinall, 2007; Freemantle, 1995; Fuchs, 2011; Green, 2007; Grimshaw 
J. M., 2012; Grimshaw J. M., 2004; Institute of Medicine, 2001; Oxman, 1995).   
The Cochrane Collaboration has published a number of formal systematic reviews of 
published studies and literature reviews exploring the effectiveness of specific behavior-change 
interventions aimed at physicians (Cochrane Effective Practice and Organisation of Care Group, 
2012; Edwards, 2009; Flodgren G. E., 2011; Flodgren G. P., 2011; Freemantle, 1995; Giguère, 2012; 
Ivers, 2012; O’Brien, 2008; Pantoja, 2009; Satterlee, 2008).  The table below displays a summary of 
intervention types, along with their relative ability to motivate desired changes in physicians’ 
behavior. 
Table 2 - Interventions Aimed at Changing Physicians' Clinical Behavior  
Intervention category Magnitude of effect 
Printed education materials (passive dissemination) Small 
Medical education meetings  
Didactic lectures Small 
Interactive sessions Moderate 
Didactic and interactive combined (no better than interactive alone) Moderate 
Educational outreach Small to moderate 
Opinion leaders Large 
Audit and feedback Small to moderate 
Reminders (paper and electronic) Small to moderate 
Financial incentives  
Limited duration contracts No effect 
Payment for each service, episode or visit Small 
Payment for providing care for a specific patient population Small 
Adhering to pre-specified treatment or quality targets Small 
Mixed systems No effect 
 
No single-pronged approach or combination of approaches works consistently and reliably to 
motivate changes in physician behavior.  However, complex multi-faceted interventions combining 
several of the approaches listed above show promise.   
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The benefits of increasing use of EGFR testing are unmistakable and appear now to be 
irrefutable (Cataldo, 2011; Gazdar A. , 2010; Lennes, 2011; Maione, 2010; Printz, 2010; Shepard F. 
A., 2011; West J. H., 2010).  Even so, adherence to clinical practice guidelines recommending routine 
use of EGFR testing remains much lower than might be expected after sustained efforts to motivate 
oncologists to adopt testing as standard practice when caring for patients with NSCLC (Alt, 2011; 
Chustecka, 2013; Lynch J. A., 2013).   
There are a number of factors that can influence a physician’s decision to use EGFR testing; 
however, little is known about how oncologists weigh various factors when making decisions.  Chapter 3 
describes the research methodology for beginning to identify the factors influencing oncologists’ 
decisions about the use of EGFR tests when treating patients with advanced or metastatic NSCLC.  The 
insights and understanding gained from this research and the literature review will help inform the plan 
for increasing the use of EGFR testing outlined in chapter five. 
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CHAPTER 3 - METHODS 
Research Purpose  
The goal of this research was to begin identifying factors oncologists consider when deciding 
whether to perform EGFR testing of lung tumor samples taken from patients with advanced or 
metastatic NSCLC.  It was anticipated that some factors would be more important than others to 
individual physicians with some factors increasing the likelihood an oncologist will order an EGFR 
test for a specific patient and others weighing against testing.   
Introduction   
The Lynch data presented at the 2011 American Association for Cancer Research (AARC) 
Cancer Disparities Conference, and the subsequent publication of the research results in Genetics in 
Medicine in 2013, indicate EGFR mutation testing is vastly underused by oncologists treating patients 
with lung cancer in the U.S. (Alt, 2011; Lynch J. A., 2013).  A pair of recent articles by Chustecka 
suggest testing rates may have improved in major cancer centers and academic medical centers since 
the Lynch data were published, but remain low in community oncology practice settings (Chustecka, 
2013; Chustecka, 2013).   
Although there is a significant body of evidence showing that using the molecular profile of a 
patient’s lung cancer tumor is the most reliable method of selecting from among available treatment 
options, EGFR testing is seldom done in most geographic locations.  Instead, treatment selection is 
usually based on clinical judgment or patient phenotypic (observed) characteristics, which are largely 
ineffective means of predicting a patient’s likely response to erlotinib (Shepard F. A., 2011).
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A thorough review of clinical and behavioral literature, medical media, and the Internet revealed 
no published data, qualitative or quantitative, identifying the reasons behind the variability in the use of 
EGFR testing by oncologists.  Thought leaders in the lung cancer research and clinical practice 
communities--who treat a small percentage of cancer patients--have speculated about the reasons why 
other oncologists do not routinely use the widely available tests (Cataldo, 2011; Gandara, 2010; Hirsch, 
2006; Lennes, 2011; Maemondo, 2010; Maione, 2010; Nierendgarten, 2010; Shepard F. A., 2011; West, 
2010).  However, experts were not the subject of interest in this research, nor do they appear to have any 
objective proof their opinions about the behavior and motivation of others reflect the actual beliefs and 
actions of their colleagues.   
The research study was done to begin understanding why some community-based oncologists do 
not routinely perform EGFR tests; this step was necessary before a plan could be developed for 
motivating more routine use.  Key informant interviews were used to gather data; the interviews provided 
an opportunity to hear directly from community oncologists who treat NSCLC about how they decide 
whether they’re going to order EGFR tests for the patients they are treating.  The interview format 
allowed the researcher to develop deeper insights and understanding than structured quantitative 
questionnaires or surveys.  The interviews also facilitated deeper exploration into the thought processes, 
behaviors and perceptions of research subjects.   
Ethics Approval 
Ethics approval was obtained from the UNC Public Health-Nursing Institutional Review Board 
(study #13-2569, 7-26-2013), and verbal consent was obtained from each subject at the beginning of their 
interview. 
Study Population 
The research component of this disseration involved semi-structured telephone interviews with 18 
to 20 practicing community oncologists.  Because of the narrowness of the research topic, selective 
sampling was used to identify research subjects who have experience diagnosing and treating patients 
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with advanced and metastatic NSCLC.  Because 85% of all individuals with NSCLC present with late 
stage disease, oncologists treating patients with lung cancer are higly likely to have extensive experience 
managing patients who are candidates for EGFR testing (American Cancer Society, 2013).  Oncologists’ 
experience treating this patient population was confirmed twice, once during the recruitment process and 
again at the beginning of the telephone interview.   
A targeted strategy was used to identify research subjects.   Oncologists were identified from the 
web sites of state oncology associations, community hospitals, oncology practices, and lung cancer 
advocacy groups; emphasis was placed on recruiting oncologists who treat patients with NSCLC in North 
Carolina and other southern states.  Physician names were cross referenced to their medical practice web 
sites to identify prospectively—to the extent possible--oncologists who treat lung cancer and to confirm 
their contact information.   
Jared Weiss, M.D., Assistant Professor, Thoracic, Head and Neck Cancer Programs, University 
of North Carolina Chapel Hill provided assistance and advice during the recruitment phase of the key 
informant interviews.  
Study Recruitment 
After a list of potential subjects was compiled, a personalized email (Appendix B) was sent 
inviting them to participate in the study.  Oncologists who did not have published email addresses were 
recruited by telephone (Appendix C) instead of by email.  The invitation had information about the 
purpose of the study, the type of information sought, details about the interview (e.g., length of time, 
recording), and communicated clearly that the research was being conducted independently without any 
external funding.  The study was done in partnership with the Lung Cancer Initiative of North Carolina to 
increase the speed of recruitment.  Oncologists usually have little free time for non-clinical activities; 
therefore, they were assured the interview would last no longer than 30 minutes.   
Recipients were asked to respond by email or verbally indicating their willingness to participate 
in the interview and confirming they treat patients with advanced or metastatic NSCLC.  Follow-up 
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telephone calls were made to anyone who did not respond to the initial invitation within a week.  A 
second follow-up call was made three to five days later to anyone who still had not responded.  A 
maximum of two follow-up telephone calls were made to oncologists who did not respond to the initial 
communication.  Non-responders were considered non-contactable and were removed from the list of 
potential research participants. 
Interview scheduling was done during the recruitment phone calls or in follow-up emails.  An 
email confirmation was sent immediately to each participating oncologist with the date and time for the 
interview, along with the toll-free dial-in information and conference code.  A final reminder email was 
sent to the oncologists 24 to 48 hours before the interview. 
Interview Overview 
After consent was obtained, the interviews began with a brief overview of the purpose of the 
study to help orient study participants to the task, along with the importance of their participation; they 
were reminded the interviews were being recorded so they could be transcribed verbatim for analysis 
purposes.  Subjects were encouraged at the beginning and throughout the interview to elaborate when 
responding to questions.  The interviews were semi-structured; the interview guide ensured the question 
wording and order were consistent across interviews.   
A pseudonym was assigned to each participant and personally identifiable information was 
excluded from this manuscript to protect the confidentiality of study participants. 
The interview guide had five sections, as shown below.  The complete interview guide can be 
found in Appendix D.   
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Figure 4 - Interview Guide Overview 
I. Introduction 
II. Specialty and practice related questions 
III. EGFR testing questions 
IV. Closing 
V. Thank you 
 
Telephone and Audio Recording Technology 
The telephone calls were conducted using freeconferencecall.com, which provides free web-
based conference call services and high quality audio recording capabilities eliminating the need for a 
separate recording device (Global Conference Partners).  A small fee was paid to secure a toll-free dial-in 
number to eliminate any long distance fees for participants. 
Analysis Plan 
A deductive approach was used to identify a priori categories based on the research done during 
the literature review phase.  Factors influencing a physician’s decision to perform pre-treatment EGFR 
testing were separated into two broad categories and then further divided into sub-categories of factors an 
oncologist may weigh when making decisions about ordering EGFR tests for patients with advanced or 
metastatic NSCLC.  The majority of the factors can influence a physician’s decision to perform EGFR 
testing in either direction depending on the oncologist’s perceptions, experiences, training, behaviors, and 
beliefs.  
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Figure 5 - Data Analysis Framework: A Priori Coding Categories 
 
The audio recordings from the interviews were transcribed verbatim.  The transcribed text 
was imported into MAXQDA 11, which is the qualitative data analysis software program that was 
used for coding the transcripts and content analysis (MAXQDA).   
The researcher reviewed the transcribed interviews to confirm the presence of the two major 
categories and any factors that fit into the decision criteria/influencer categories displayed in the 
diagram above.  No additional categories were identified during the coding and analysis processes; all 
factors mentioned by the key informants fit into the established data analysis framework.   
A descriptive analysis of the research findings is presented in chapter four. 
Study Limitations  
A thorough literature search was conducted via the Internet using standard databases 
including PubMed Central, CINAHL, Cochrane Collaboration, ScienceDirect, Public Library of 
Science (PLoS), BioMed Central, Science.gov, FindArticles, and Medscape, along with the Google 
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Internet search engine.  However, it is possible published or unpublished quantitative or qualitative 
research data or studies were missed during the investigation.  In any event, the results of this 
research effort will add to any knowledge and data available on the subject. 
The quality of the research in the reviewed literature about lung cancer and lung cancer 
treatments is very good; it provides relevant information supporting the need for and value of this 
research project.  Information about factors influencing physicians' clinical behaviors and decisions 
discussed in part two of chapter two (Appendix A) is readily available.  The number of studies 
evaluating specific interventions aimed at modifying the clinical behavior of oncologists is extremely 
limited; therefore, the literature review was broadened to include other medical specialists, including 
primary care physicians.  It is possible research findings from studies done with physicians in other 
medical specialties are not generalizable to oncologists; there is no published research confirming or 
refuting the generalizability. 
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CHAPTER 4 - RESULTS 
Subject recruitment was more successful than anticipated.  Twenty-three (vs. 20 expected) 
community oncologists participated in the study.  All interviews were conducted by telephone 
between August 19 and October 14, 2013, and were transcribed verbatim; the average length of the 
interviews was 19.5 minutes (range 11 to 26 min.).  Data coding and analysis was performed using 
MAXQDA 11.   
Key Informant Characteristics 
 All participants met the inclusion criteria.  They all practice general oncology and currently 
treat patients with advanced or metastatic non-small cell lung cancer.  All participants practice in the 
southern U.S.  Over three-quarters (78%) are located in North Carolina; the remaining oncologists 
practice in Florida (1), Georgia (1), Louisiana (1), and Virginia (2).   
 Additional descriptive characteristics associated with the study cohort were captured during 
the interviews.  All participants have completed their oncology training.  The percentage breakdown 
by years in oncology practice is 39% (n=9) have been practicing ten years or less, 21.7% (n=5) 
between 11 and 20 years, 26% (n=6) between 21 and 30 years, and three have been in practice over 
30 years.  All of the oncologists practice in community settings; twenty are in private practice and 
three are employed by community-based non-profit hospitals.  The average number of patients with 
advanced and metastatic NSCLC treated per month ranged from five to 50.  Seventeen oncologists 
(74%) treat between five and 20 patients per month, three treat between 21 to 30 patients per month, 
two treat between 31 and 40 patients per month, and one treats an average of 50 patients per month.   
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Table 3 - Summary of Key Informant Characteristics 
Characteristic Frequency 
Specialty - general oncology 23 (100%) 
Practice location  
North Carolina 18 (78%) 
Florida 1 (4.4%) 
Georgia 1 (4.4%) 
Louisiana 1 (4.4%) 
Virginia 2 (8.8%) 
Employment  
Private practice 20 
Employed by a hospital 3 
Length of time since completing oncology 
training  
0 to 10 years   9 (39%) 
11 to 20 years 5 (21.7%) 
21 to 30 years 6 (26.2%) 
30+ years 3 (13.1%) 
Average number of patients with advanced or 
metastatic NSCLC treated per month 
 
1-10 patients 8 (34.8%) 
 
11 to 20 patients   9 (39.1%) 
21 to 30 patients 3 (13%) 
31 to 40 patients 2 (8.7%) 
41 to 50 patients 1 (4.4%) 
Percent of NSCLC patients with advanced or 
metastatic disease 
 
Up to 70% 6 (26.1%) 
71 to 80% 8 (34.8%) 
81 to 90% 7 (30.4%) 
91 to 100% 2 (8.7%) 
Frequency of EGFR Testing 
The oncologists were asked about their frequency of use of EGFR testing (always, 
sometimes, never) when treating patients with advanced or metastatic NSCLC.  Eight physicians 
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(34.8%) reported testing every patient; nine (39.1%) test some of their patients; and the remaining six 
(26.1%) never perform EGFR tests.   
Figure 6 - Frequency of EGFR Testing 
 
A Student’s t-test (independent variables, one tailed, unequal variances (type 3)) was used to 
evaluate the characteristics and behavior-related information collected to determine which 
characteristics, if any, were significantly associated with oncologists who use EGFR mutation tests 
compared with  those who do not.  A p-value < .05 was considered statistically significant. 
 Having a higher percentage of patients with more severe NSCLC did not influence 
physicians’ testing behaviors, nor did employment type (private practice vs. hospital, p = .45).  
However, oncologists treating a higher average number of patients with advanced or metastatic 
NSCLC per month were significantly more likely to test at least some of their patients (p = .005).  
Those who reported never using EGFR tests treat an average of 10 patients per month, those who 
sometimes order tests treat an average of 19 patients per month, and oncologists who always order 
tests treat an average of almost 22 patients per month.  The difference in the average number of 
Always  
35% 
Sometimes 
39% 
Never 
26% 
Frequency of EGFR Testing 
N=23 
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patients treated per month between those who sometimes test compared with those who always test 
was not statistically significantly different (p = .309).   
Time elapsed since completion of oncology training also had a significant impact on testing 
behavior.  Of the nine oncologists who completed their specialty training within the past ten years, 
eight reported testing all of their patients and one tests some patients; this group was significantly 
more likely to perform EGFR tests than those who have been practicing oncology longer than ten 
years (P < .05).  Five participants completed their training between 11 and 20 years ago; of those, 
three sometimes test patients and two never do.  Five oncologists completed their training between 21 
and 30 years ago; four of them test some patients and one does not.  The three physicians who have 
been in practice over 30 years never order EGFR tests.  All groups were significantly more likely to 
order an EGFR test than oncologists who completed their oncology training more than 30 years ago 
(P < .05).  
Figure 7 - Testing Frequency by Years in Oncology Practice
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Table 4 - Characteristics and Their Impact on EGFR Testing Rates 
 
Characteristic 
Statistically significant difference in use of 
EGFR testing? 
Yes No 
Percent of patients (higher vs. lower) with NSCLC 
with more severe disease  
  
X 
Employment type (private practice vs. hospital 
employee) 
  
X 
Average number of patients with advanced or 
metastatic NSCLC treated per month (higher vs. 
lower) 
 
 
X 
 
Time elapsed since completion of oncology training 
(shorter vs. longer) 
 
X 
 
Future Use of EGFR Testing  
Physicians were asked, “Do you expect your future use of EGFR testing to increase, decrease, 
or stay the same?”  No one was planning to decrease his or her use of EGFR testing in the future.  
Seventeen physicians expect their use to remain at the current level and six expect their use to 
increase or are unsure whether their use will increase or remain the same.  The eight oncologists who 
routinely order EGFR tests for all of their patients expect to continue testing all of their patients.  Of 
the nine physicians who test some patients, five expect their use will remain steady, two believe they 
will increase their use, and two are unsure.  Four of the six (67%) physicians who report never using 
EGFR tests expect they will not begin testing patients; three of the four have been in practice 30 years 
or longer.  The two remaining “never” respondents said they will begin testing in the future.                                                 
Facilitators and Barriers to Use of EGFR Testing  
The primary goal of the key informant interviews was to learn directly from general 
oncologists the facilitators and barriers to their use of EGFR testing in the management of patients 
with advanced or metastatic NSCLC.  Study participants were asked to identify the main reasons they 
do or do not order EGFR tests, as well as the most compelling drivers and barriers to testing.  The 
influencers and barriers are discussed below and illustrated by quotes from study participants. 
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 It was anticipated there would be sub-categories within the main categories of facilitators and 
barriers based on the literature review including physician-specific factors (e.g. training, experience); 
patient-related (e.g. health, willingness to be tested); EGFR test-specific (biopsy required, length of 
time to get results); clinical evidence and practice guidelines; and a general category for other 
influencers.  These influencers can be classified as either facilitators or barriers depending on the 
responses provided by individual physicians.  While influencers falling into all of categories were 
mentioned during the interviews, some were mentioned much more frequently than others were.   The 
clinical literature and practice guidelines category dominated the facilitators named by oncologists 
who perform EGFR tests and two different categories--patient-related and physician-specific factors--
dominated the barriers cited by those who sometimes or never perform EGFR tests.  
Facilitators of EGFR testing.  Oncologists who reported testing some or all of their patients 
were asked, “What are your main reasons for ordering EGFR mutation tests for your patients?” and 
“Is there any one thing that stands out in your mind as a particularly compelling reason to test your 
patients?”.  The six oncologists who never test patients were not asked these questions; however, one 
of them mentioned during the interview they would consider testing at least some patients if a trusted 
colleague recommends it.   
  Clinical literature and practice guidelines.  This was the most frequently mentioned factor 
influencing the decision to use EGFR testing.  The eight oncologists who always test and seven of the 
nine who test some patients mentioned clinical literature and practice guidelines as the most 
compelling reason to perform pretreatment EGFR testing because it has been shown definitively that 
testing results in better treatment outcomes; it also provides a degree of confidence when making 
treatment decisions.  The following quotation is representative of the responses gathered from these 
15 physicians, “The clinical literature is clear that choosing treatment based on the EGFR status of 
patients with advanced non-small cell lung cancer produces the best outcomes.  Patients with EGFR 
mutations can have a dramatic response to erlotinib but those without a mutation get better results 
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with chemotherapy.  Not only do EGFR test results guide my first treatment decision, they provide 
guidance for follow-on treatment.”  
Two participants mentioned following the National Comprehensive Cancer Network (NCCN) 
treatment guidelines for non-small cell lung cancer.   
Even when probed for additional reasons for ordering EGFR tests, none of the participants 
mentioned any other factors that influence their decisions.   
Patient-related factors.  Of the two remaining oncologists who test at least some patients, 
one tests only those patients who ask to be tested and the other tests only those patients who prefer to 
use oral therapy over chemotherapy to determine prospectively whether the patient has an EGFR 
mutation that would make them more likely to respond to treatment.   
Other influencers.  One of the eight oncologists who test all of their patients mentioned that 
testing is done reflexively (automatically) by the pathology department on all NSCLC tissue biopsies 
performed at their local hospital.  “I don’t even have to think about it.  It was not always this way.  
My partners and I worked with the hospital pathologist to get it done automatically.  It’s the right 
thing to do based on the clinical literature.”  One oncologist who tests some patients was motivated to 
start ordering EGFR tests after it was recommended by a respected colleague.   
Physician-specific and EGFR test-specific.  None of the responses fell into either of these 
two sub-categories. 
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Figure 8 - Facilitators by Prevalence of EGFR Testing 
 
Barriers to EGFR testing.  All study participants--including those who reported always 
ordering EGFR tests--were asked the following two questions, “What is the main reason or reasons 
you decide not to order an EGFR mutation test for a patient?” and “Is there any one thing that is the 
most compelling reason for not testing your patients?”.  The eight oncologists who test all of their 
patients were also asked the questions to determine if there is any situation that causes them to avoid 
testing a patient.  All responses were grouped into the five sub-categories mentioned above.    
Patient-related factors.  The health of a patient plays a significant role in the decision not to 
perform EGFR tests for many physicians; it was the most frequently mentioned barrier to testing.  Of 
the eight who reported testing all of their patients, all but one reported there are patient-specific 
circumstances that preclude testing, including patients who are too sick to undergo a biopsy; those 
who are in hospice care or actively dying; and those who refuse to be treated.  One physician tests 
every patient—including those in hospice—because individuals with an EGFR mutation are highly 
likely to respond to targeted treatment regardless of their health status.  If a patient tests positive for 
an EGFR mutation, they are withdrawn from hospice and started on erlotinib.  Patients who do not 
harbor an EGFR mutation remain in hospice.  All of the nine doctors who test at least some of their 
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patients cited similar situations where they avoid testing; in addition, this group also mentioned other 
factors, including: the physical condition of the patient (frailty); patient refusal to be tested; lack of 
(patient) understanding of the importance of EGFR testing; and pressure from the patient and 
patient’s family to begin treatment immediately. 
Physician-specific factors.  Of the oncologists who sometimes or never use EGFR testing, 
the nine who sometimes test (100%) and four who never test (67%) used a variety of words and 
phrases that suggest they are confident in their ability to select the best treatment for a patient based 
on their clinical judgment and experience; this was the second most frequently cited barrier to EGFR 
testing.  The following three quotes are illustrative of the self-confidence theme.  “I really don't need 
to test most of my patients because I rely on previous experience to select the best treatment for a 
given patient.”  “I don't believe it is necessary.  There is data showing testing is a nice to do but not 
necessary.”  “I'm not convinced testing a patient is any better than using my clinical judgment.  I’ve 
been doing this a long time.  I believe I know what is best for the patient, so there is no reason to test 
them.”    
The two other physicians who never test patients said they do not know enough about EGFR 
testing to make a well-informed decision about using it.   None of the oncologists who test all of their 
patients mentioned any physician-specific factors.   
EGFR test-specific factors.  Test-related factors were mentioned by 9 physicians (5 
sometimes and 4 never testers); they included cost, length of time it takes to get results, the need for a 
biopsy, and insufficient tissue available to perform the test.  The following quote is from an 
oncologist who decided to give testing a try and subsequently decided the downsides of testing 
outweigh the benefits, “I did it a couple times but found it to be a big hassle.  It requires a good 
biopsy and we have to send the sample out to be tested by a lab.  It takes time to get results and in the 
meantime, people are not being treated.  I don't think that's a good way to practice medicine.” 
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Clinical evidence and practice guidelines.  Five oncologists—including three who test some 
patients and two who never test—indicated a need for additional proof that EGFR testing leads to 
better treatment outcomes.  One doctor who tests some patients said, “I would say that it's too soon to 
tell if using EGFR testing is going to help my patients so I'm not ready to test everyone. If I’m going 
to start someone on chemotherapy there’s no reason to test.”  Another mentioned, “Guidelines are just 
that, guidance and are not required.”  A third oncologist who never uses EGFR testing said, “I need 
more proof that testing is worth the effort.” 
Other influencers.  One oncologist who does not use EGFR testing mentioned that no 
colleagues do it either.   
Figure 9 - Barriers by Prevalence of EGFR Testing 
 
Discussion 
Twenty-three general oncologists who practice in community settings participated in the key 
informant interviews.  They all practice in the southeastern US and completed their oncology training 
prior to being interviewed.  Participants were asked whether they always, sometimes or never perform 
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EGFR tests on patients with advanced or metastatic NSCLC.  Eight of the twenty-three reported 
testing all of their patients, nine test some patients, and six never use the test.   
Having a higher percentage of patients with NSCLC who have advanced or metastatic disease 
and employment situation—private practice vs. being employed by a hospital—did not influence the 
likelihood of performing EGFR tests.  However, two characteristics were associated with an increased 
likelihood of performing EGFR testing on at least some patients; these included treating an average of 
more than ten patients with advanced or metastatic NSCLC a month, and length of time since 
completion of oncology training.  Oncologists who have been in practice ten years or less were 
significantly more likely to test at least some patients than physician who have been in practice 
longer; those who have been in practice over 30 years were the least likely to use EGFR testing.   
The factors influencing a physician’s decision to perform EGFR testing were categorized as 
facilitators or barriers.  In addition to these two main categories, five sub-categories were identified a 
priori, including: physician-specific factors (e.g. training, experience); patient-related (e.g. health, 
willingness to be tested); EGFR test-specific (biopsy required, length of time to get results); clinical 
evidence and practice guidelines; and a general category for other influencers.  Participants 
mentioned three categories of facilitators (patient-related, clinical evidence and practice guidelines, 
and other influencers) and all five were cited as barriers.  
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Figure 10 - Summary of Category Mentions by Key Informants 
 
The most commonly mentioned facilitator was clinical literature and practice guidelines, and 
the second most common was patient-related factors, followed by other influencers.   The most 
commonly mentioned barrier was patient-related factors, followed by physician-specific, test-specific, 
clinical literature and guidelines, and other influencers.  A consistent theme emerged during the 
discussion of barriers to testing.  Thirteen physicians, including all nine “sometimes” testers and four 
“never” testers used words and phrases suggesting they are confident in their ability to make the best 
treatment decisions for their patients based on their clinical judgment and experience, which obviates 
the need for EGFR testing. 
Study Limitations 
A thorough search of the Internet suggests this may be the first study done with the intention 
of understanding the factors that influence a community oncologist’s decision about performing 
EGFR mutation tests on patients with advanced or metastatic NSCLC.  The key informant interviews 
provided the opportunity for oncologists to share their personal experiences, beliefs, and behaviors in 
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their own words in a confidential setting.  However, time and resource constraints limited the number 
of interviews that were conducted.   
Twenty-three community-based oncologists participated in the study.  The study participants 
were purposely selected for their knowledge and experience treating lung cancer patients; they all 
practice oncology in the southern U.S.  Therefore, the cohort may not be representative of community 
oncologists practicing throughout the U.S.  Based on time and resource constraints, the number of key 
informant interviews was limited.  It is possible there are additional factors influencing oncologists’ 
decisions about EGFR tests that were not identified during the interview process.  In order to increase 
the reliability and generalizability of the data, it is important that a larger study involving more 
oncologists across a wider geographic area and with a greater variety of practice types be conducted 
in the future.   
Despite the limitations outlined above, the data collected combined with information 
uncovered during the process of researching and writing the literature review (Appendix A) provided 
sufficient guidance for creating the plan for increasing the pretreatment use of EGFR testing that is 
presented in chapter five.  Kotter’s eight-step process for change was used as the framework for 
developing the implementation plan. 
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CHAPTER 5 – THE IMPLEMENTATION PLAN 
 The findings of this study, although not generalizable, provide valuable insight into the 
thought processes of community oncologists treating patients with late stage NSCLC.  These data, 
along with information gathered during the literature review, provide a foundation for formulating an 
approach for increasing the use of EGFR testing based on John Kotter’s eight-step process for 
change, which was originally described in his book, Leading Change (Kotter, 1996).  Each of 
Kotter’s eight steps, including creating a sense of urgency, forming a powerful coalition, creating a 
vision for change, communicating the vision, overcoming obstacles, creating short-term wins, 
building on the change, and anchoring change in the culture are discussed in detail below.   
 Interventions will be aimed at three target audiences, including community oncologists; other 
healthcare professionals; and lung cancer patients, their families, caregivers, and advocates.  Not all 
of Kotter’s steps apply to the all three constituencies. 
Implementation Plan  
This implementation plan focuses on increasing the use of EGFR testing in the state of North 
Carolina.  The majority of community oncologists interviewed for this research practice in North 
Carolina; they provide a window into the perspectives and behaviors of others who practice here.  
Why am I starting on a small scale, given the magnitude of the problem?  The literature review covers 
a wide range of interventions used commonly to motivate physicians to change their clinical practices 
and habits (Table 2, p. 13); very few are consistently successful and most have limited impact.  
Because literature on clinical practice behaviors of oncologists was scarce, the information regarding 
the impact of various tactics included in this dissertation came primarily from studies conducted with 
physicians in other specialties.  Initial efforts within North Carolina will provide data specific to the 
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impact of interventions on EGFR testing rates, albeit on a small scale.  Each tactic implemented in the 
NC pilot will be evaluated after completion to identify interventions that work best to motivate an 
increase in EGFR testing by community oncologists before rolling them out to a broader audience.  
Nationwide outreach and education efforts are extremely expensive and it is highly unlikely sufficient 
funding will be available without proof that tactics used produce meaningful results.  Using a pilot 
approach provides an opportunity to evaluate tactics and collect the data necessary for fundraising to 
support a national campaign.  It also conserves resources by avoiding ongoing use of tactics that do 
not produce meaningful results.   
Creating a Sense of Urgency 
Creating a sense of urgency is the crucial first step for initiating change.  There are 
compelling reasons for increasing the rate of EGFR testing.  The first step in creating a sense of 
urgency is making professional and patient groups aware that there is a variance in testing rates and 
sharing the facilitators and barriers to testing uncovered during this research.  Eight of the oncologists 
interviewed reported testing all of their patients; they were uniformly shocked to learn that many of 
their colleagues do not.  These oncologists consider testing to be the standard of care and assume all 
of their colleagues concur.  Responses from these eight oncologists suggest that oncologists who are 
in the position to help reverse the trend might not even be aware of the existing disparities; making 
them aware of the published data and these research results is a critical step in beginning the process 
of change.     
Background information about the variation in testing rates and the study results will be 
shared with the North Carolina Oncology Society (NCOS), the statewide professional organization 
for oncologists.  This information will allow them to participate in developing training and 
educational programs aimed at breaking down barriers to testing.  I will enlist the help of Dr. Weiss 
who provided assistance and advice during the recruitment phase of the key informant interviews, and 
Dr. Jennifer Garst, M.D., a lung cancer specialist practicing at the Duke Raleigh Cancer Center, 
Raleigh, NC, who is a member of the Board of Directors of the Lung Cancer Initiative of North 
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Carolina.  They are members of NCOS and are in a position to provide advice on the best way of 
capturing the attention of the appropriate individuals in NCOS to help speed access and sharing of 
information.  
The Lung Cancer Initiative of North Carolina (LCI), an advocacy organization, was a 
partner in this research.  They have seen the results and already have a sense of urgency about 
this issue because they understand testing impacts the quality of care received by lung cancer 
patients in North Carolina.  I presented the study results to LCI members including patients, 
advocates, and health care professionals at their annual meeting and volunteer recognition dinner 
held on February 9, 2014, in Durham, North Carolina.  I am working with LCI to explore ways of 
breaking down barriers to testing from both the physician and patient perspectives.  
  Genentech, the pharmaceutical company marketing erlotinib has asked me to share the study 
results with them.  They understand the importance of tying the prescribing of erlotinib to EGFR 
testing results so that patients get the best possible treatment even if it results in the prescribing of 
other medications  (Genentech, 2014).   Genentech will be part of the planning process and will help 
implement the integrated plan for increasing EGFR testing rates.  Pfizer, another pharmaceutical 
manufacturer has also expressed interest in learning more about this study and participating in efforts 
to increase molecular testing rates.  Admittedly, pharmaceutical companies are interested in this 
research because it will help them increase sales, but their participation and support also serves the 
greater good of increasing testing rates.    
Forming a Powerful Coalition 
  A well-established patient advocacy group (LCI) and a professional organization (NCOS) 
already exist in North Carolina.  They collaborate and cooperate on efforts to decrease death from 
lung cancer and improving quality of care and life for people with lung cancer through research, 
awareness, education and access programs.  The NCOS has an ongoing advocacy program supporting 
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state funded cancer initiatives (North Carolina Oncology Society).  The LCI is the only established 
advocacy organization focused specifically on the care of lung cancer patients in North Carolina.   
Pharmaceutical manufacturers provide significant financial, educational, and logistical 
support to these two organizations.  For years, drug companies were opposed to testing, which they 
saw as limiting the use and revenue for targeted therapies.  However, they are now supporting efforts 
to increase molecular testing for EGFR and other mutations that predict response to specific 
treatments.  Together, the LCI and NCOS, with support from pharmaceutical manufacturers, and 
individual and corporate donors have the combined resources and contacts to reach a large number of 
community oncologists and lung cancer patients in North Carolina.  The first step, however, is for 
them to commit to working together to create complementary initiatives for influencing physicians 
and patients to establish a dialogue about EGFR testing, regardless of who initiates the conversation.   
Drs. Garst and Weiss are active members of both North Carolina-based organizations and are 
in the best position to bring them together to tackle this problem.  I will ask them to facilitate a 
meeting between the two organizations and personnel from pharmaceutical companies to establish an 
EGFR testing task force to begin working on a vision and plan for increasing the use of EGFR testing 
in North Carolina.  I will be a founding member of the task force. 
Creating a Vision for Change 
This research provides extra impetus for change because, for the first time, specific 
facilitators and barriers to testing were uncovered and can be addressed.  The LCI and NCOS already 
support and communicate the importance of pretreatment EGFR testing to their members.  However, 
working together on the EGFR testing task force, and with other partners, they can make a bigger 
impact than working alone.  In addition to having people representing different perspectives and 
constituencies, task force members must have a variety of complementary skills, including strategy, 
marketing, and implementation in order for the group to be successful.   
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 The first responsibility of the task force will be developing a vision statement to guide the 
work of the group.  A vision statement is the formal statement of an organization’s purpose in the 
context of its values; it helps ensure all members are working toward the same end, which facilitates 
cooperation and achievement of the vision.   Creating a vision statement without expert guidance is 
more difficult than it seems, and often results in a confusing combination of vision, mission, and 
values statements.  I will ask Leslie Burnside, MHA, who is an expert in visioning, to work with the 
task force to develop a powerful vision.  She will also help develop a mission statement defining the 
purpose of the group.   
  Having a vision and mission is not enough—the task force must also establish overarching 
objectives supporting achievement of the group’s vision and mission.  The objectives will be specific, 
measureable, attainable, reasonable, and time bound.  Without shared objectives, task force members 
could go off on their own, undermining the value of forming a guiding coalition to tackle this issue.   
Communicating the Vision 
  The task force will develop a comprehensive communications plan supporting the 
achievement of the overarching objectives; the various tactics in the plan will be integrated so they 
build on each other to maximize impact and motivate desired behavior.  Every tactic in the plan will 
have measureable objectives ensuring tactics contribute to achieving the group’s overarching 
objectives.  In addition to other measures, the task force will ask manufacturers of EGFR tests to 
provide monthly counts of tests performed in North Carolina, which will be monitored for changes 
over time.  The tactics achieving their objectives will be implemented on a national level as soon as 
possible without waiting for completion of other tactics in the communications plan; this approach 
facilitates a faster ramp-up on a broader scale.  Tactics not producing the desired results will be 
discontinued to minimize wasteful expenditure of human and financial resources.    
  One of the strategies in the communications plan is for task force members to communicate 
results of the study, along with the vision, mission, and objectives of the task force to the leaders and 
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members of their respective organizations, as well as to the broader lung cancer community.  A press 
release explaining the work of the task force, summarizing study results, and providing directions 
about how and where to obtain an EGFR mutation test will kick off implementation of the plan.  The 
release will be sent to the news and health editors at all media outlets (print, broadcast, and digital) in 
the state of North Carolina.  Follow-up phone calls will be made to news organizations pitching the 
story and making task force members and others available for interviews.  All spokespersons will be 
media trained to ensure they can communicate the key talking points effectively. 
Overcoming Obstacles  
As noted in chapter 4, there were a number of barriers mentioned during the key informant 
interviews.  The task force will take a strategic multi-pronged approach to overcoming the barriers by 
targeting communications to a number of audiences, including community oncologists, other 
healthcare professionals, and patients and their families, caregivers, and advocates. 
Community Oncologists.  Oncologists who test some patients are likely to be easier to 
motivate than those who never test.  They may simply be unaware EGFR testing improves 
outcomes for all patients, not just those with a mutation.  On the other hand, 87% of oncologists 
interviewed who test some or none of their patients expressed confidence in their ability to make 
the best treatment decisions for their patients based on their clinical experience and judgment 
alone.  Clinical literature indicates their confidence is misplaced.  Unfortunately, a majority of 
never and sometimes testers interviewed reported having no intention of adopting or expanding 
their use of EGFR testing, suggesting that it will take a significant amount of effort to motivate 
them to change their behavior.   
  There are two main approaches for increasing the use of testing; one is using direct influence 
on community oncologists and the other is using indirect methods of influence.  The task force has 
more control over the medium and message when communicating directly with this target audience 
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than when using third parties—including pathologists, hospital laboratory managers, oncology nurses, 
and patients—to influence community oncologists.   
  Some physicians interviewed want more proof EGFR testing produces better outcomes and 
others admitted to being ill informed about testing.  It is clear from the responses education is an 
essential strategy for increasing the rate of testing.  Oncologists must have knowledge and 
understanding of the critical role testing plays in delivery of high quality care before they can be 
motivated to use it.  What tactics should be used for educating oncologists?  As noted in the literature 
review, there is substantial variability in the impact of change efforts, which indicates a need to offer 
a range of educational experiences in a variety of settings and formats.  When creating the 
communications plan, the task force will focus on interventions known to have a higher likelihood of 
successfully motivating behavior change in physicians.   
  Peer influence is arguably the most reliable method of influencing physician behavior. 
Identifying and including local and regional thought leaders in the planning stage will help ensure 
their alignment with the vision and mission of the task force.  Task force members have relationships 
with oncologists who practice in North Carolina; they will use their networks to identify and engage 
oncologists respected by their peers.  Members of the task force will decide who among them is best 
suited to recruit individual thought leaders to participate in the outreach efforts.  The thought leaders 
recruited will be asked to take advantage of any opportunity—casual or formal--they have to talk to 
peers about the importance of molecular testing.    
  Thought leaders will be invited to collaborate with the task force on development of develop 
two turnkey communication kits—one for professional audiences and one for consumers.  The kits 
will include customizable templates for event invitations and awareness posters; a customizable 
program announcement for distribution to local media outlets; slides; draft agendas; talking points; 
handouts; and a list of speakers.  Kit components will be able to be used in any combination 
depending on circumstances and specific audience needs.  The kits will facilitate delivery of 
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consistent, concise and compelling communications regardless of the sophistication of the audience.  
Studies show interactive educational methods are more effective at motivating behavior change than 
passive methods or a combination of the two; therefore, the kits will include interactive exercises for 
use in engaging audience members during presentations. 
 One issue that has not yet emerged in the literature or during my research, but that would 
add weight to the argument in favor of testing, is the threat of medical malpractice lawsuits based 
on the failure to perform and base treatment on results of molecular testing.  I will ask Dean 
Harris, a member of the faculty of the Gillings School of Global Public Health, to recommend 
individuals who are knowledgeable about medical malpractice law and may be willing to research 
whether any such lawsuits exist.  If there has been successful litigation, the issue of legal liability 
will be woven into the messaging for targeted healthcare professional audiences because anyone 
participating in the direct care of patients with NSCLC is vulnerable to legal action.  
 In addition to peer influence, other means of communicating directly with community 
oncologists will be used.  Pharmaceutical companies participating in the task force have sales 
representatives that meet regularly with community oncologists with a goal of influencing 
physicians’ clinical behavior (primarily prescribing).  These companies also deploy non-sales 
field-based medical science liaisons (MSLs) that have responsibility for establishing relationships 
with influential physicians and researchers, and sharing science-based information with them 
(Cutting Edge Information, 2012).  MSLs can more effectively educate and motivate change 
because they are healthcare professionals with expert knowledge in specific therapeutic areas, 
which increases their credibility.  Physicians expect the sales representatives and MSLs calling on 
them to share new and interesting information, which provides the perfect opportunity for sharing 
clinical data about the importance of EGFR testing.  Information contained in the professional kit 
can be repurposed for use in sales materials and tablet-based education.   
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The task force will also work with the North Carolina Health Education Centers (AHEC) 
to fund and develop an accredited live continuing education program for doctors and nurses 
practicing in NC (NC AHEC, 2014).  AHEC is one of the leading providers of continuing 
education programs for health care professionals working in NC; their mission includes 
enhancing the quality of care and health outcomes for residents of North Carolina.  The program 
office, which is responsible for developing educational programming, is located on the campus of 
the University of North Carolina Chapel Hill.  AHEC has 10 regional centers across the state 
allowing them to increase access and ease of participating in educational programs and 
conferences.   The task force will supplement AHEC’s publicity efforts to increase awareness of 
the continuing education programs and boost attendance.  
Many oncologists interviewed avoid testing patients in hospice care because, by 
definition, patients in hospice receive palliative care instead of potentially curative treatment.  
However, one oncologist interviewed tests patients in hospice that have not yet been tested 
because individuals with one or more specific EGFR mutations often have an almost immediate, 
profound, and sustained response to erlotinib treatment.  Testing patients in hospice gives them a 
chance at living significantly longer with good quality of life.  Sharing this oncologist’s approach 
will likely resonate most with oncologists who already test some or all of their patients.  After 
presenting results of my research at the LCI meeting on February 9, two oncologists in attendance 
mentioned that testing patients in hospice had never occurred to them, but they are planning to 
start doing so immediately, which is exactly the response I am hoping to get when we begin 
actively educating community oncologists. Information about testing patients in hospice will be 
included in both kits.  Patients, families and caregivers are important audiences for this 
information because it will help them have the confidence to ask their oncologist to be tested.  
The community oncologist who tests his patients in hospice care has volunteered to participate in 
our education efforts.   
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Other Healthcare Professionals.  There are healthcare professionals that can influence 
community oncologists in a variety of ways to increase their use of EGFR testing. 
Pathologists.  Pathologists analyze and perform tests on tissue extracted during biopsy 
procedures.  Pathologists can increase the use of EGFR testing in two ways.  First, they can use 
their personal and professional relationships, and position in the hospital to motivate community 
oncologists to create standing orders for EGFR testing of tumors confirmed to be NSCLC.  The 
second way is by instituting reflexive testing, which is automatic ordering of laboratory tests 
based on a specific diagnosis or results of an initial test (Eastep, 2011).  Reflexive testing does 
not require any action by oncologists; it is an institutional protocol triggered by the presence of 
certain tumor characteristics. 
In June 2013, the College of American Pathologists published an evidence-based 
guideline recommending using EGFR testing to inform prescribing of targeted therapies for the 
treatment of NSCLC (College of American Pathologists, 2013).  Pathologists can use this 
guideline as proof of the value of EGFR testing, along with results of published studies.  Task 
force members will work with the North Carolina Society of Pathologists (NCSP) to leverage 
professional kit contents for use by the Society and pharmaceutical sales representatives to 
educate pathologists practicing in community hospitals about the importance of routinely 
performing EGFR mutation tests.  The materials will urge pathologists to proactively engage 
community oncologists in conversations about the role and importance of EGFR testing, and 
consider instituting reflexive EGFR testing in their hospitals.  The NCSP members will be made 
aware of AHEC continuing education programs so they can publicize the events to their medical 
colleagues. 
  Directors and Managers of Hospital Laboratories.  Managers of hospital laboratories play a 
critical role in deciding what laboratory tests will be available for their inpatients and outpatients.  
The Clinical Laboratory Management Association (CLMA) has a chapter in North Carolina (Clinical 
Laboratory Management Association, 2014).  The task force will reach out to the Carolina chapter to 
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get their input on the best way of encouraging members to be proactive about educating community 
oncologists about EGFR mutation testing and instituting reflexive molecular testing for appropriate 
lung cancer patients.  They will be encouraged to work with their hospital’s pathologist to combine 
resources to increase the effectiveness of their efforts. 
  Oncology Nurses.  Oncology nursing is a recognized nursing specialty.  Oncology nurses 
play a pivotal role in the direct delivery of cancer care to patients.  They often develop very close 
relationships with their patients, patients’ families and caregivers and, in general, spend more time 
with patients than do oncologists.  Because of the trust established through repeated patient contact, 
oncology nurses have the credibility to talk to patients about the importance of molecular tumor 
testing and motivate patients to ask for testing if it has not already been done.  The interview 
responses suggest patients may be able to motivate their oncologist to do an EGFR test simply by 
asking for it. 
  In addition to nursing education offered by the regional AHEC chapters, the Oncology 
Nursing Society (ONS) is an important educational resource for oncology nurses (Oncology Nursing 
Society, 2014); there are six chapters in North Carolina.  The vision and mission of the ONS are 
consistent with the task force’s initiative.  The task force will work with the North Carolina chapters 
of the ONS to use kit contents and components to develop educational materials and programs about 
molecular testing for their members; they will also help AHEC publicize their continuing education 
programs through the ONS chapters. 
  Patients and Their Families, Caregivers, and Advocates.  Seven of the eight oncologists 
who test all of their patients and all nine of the oncologists who test some of their patients mentioned 
patient-related issues during the barriers section of the interview.  None of the oncologists who never 
perform EGFR testing mentioned any barriers falling into this category.  Some barriers are 
insurmountable and some are potentially modifiable.  Some patients are too frail or sick to undergo 
the biopsy procedure needed to obtain a tumor sample for testing, and others are actively dying.  
Some patients refuse testing or more treatment.  Some refuse testing because they want to start 
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treatment immediately and do not want to wait to get test results to begin.  Study participants said this 
is the primary reason families often push to move forward with treatment without testing.    
  The goal of the consumer kit is increasing awareness of EGFR testing, motivating patients to 
be tested, and facilitating patient and provider discussions about testing.  The kit contents will 
communicate information in easy to understand language and graphics.  The task force will develop 
multi-language print materials (e.g. brochures, posters) and educational video content for use in 
oncologists’ offices and oncology clinics, patient and community education programs, and health 
fairs.  Pharmaceutical sales representatives and MSLs will assist by distributing the educational 
materials to oncologists’ offices and clinics.  
  One of the primary barriers to testing is the fear of waiting to begin treatment while awaiting 
test results.  Oncologists and consumer audiences will be informed that the time lapse between testing 
and receiving results is currently about two weeks and is dropping rapidly as efforts to shorten the 
waiting time even further are being pursued.   At some point, it is likely the wait time will be reduced 
to the point it is no longer a barrier.  In the meantime, educational materials will address the concerns 
about delaying treatment by communicating that patients who are tested and receive treatment based 
on test results have better outcomes even when treatment initiation is delayed.  Patient members of 
the LCI will consult with the task force during the development of the consumer kit, and will be made 
available for speaking and media engagements.  They will be media trained to deliver compelling, 
clear, and motivating information about EGFR testing.  Because family members and caregivers often 
push oncologists to begin treatment immediately, they are an important part of the target audience for 
these outreach efforts.    
  The LCI already urges the patients that contact them to go to oncologists working at 
academic medical centers or cancer centers to have molecular testing done and to have their initial 
treatment plan developed.  Patients can be treated there or opt to take the treatment plan to their local 
community oncologist.  This approach will continue and expand through additional educational 
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outreach activities on the LCI website, health fairs, and talks done at community organizations in 
North Carolina (i.e. Rotary Club).   
Creating Short-Term Wins  
Short-term wins generate momentum toward achieving the overarching objectives of the task 
force.  It is likely it will be easier to influence change in behavior in community oncologists who 
already test some of their patients than those who do not perform any tests.  One of the quickest and 
easiest ways of learning about physician practice habits is through face-to-face discussions they have 
with pharmaceutical sales representatives and MSLs.  The task force members from pharmaceutical 
companies will work with their sales representatives and MSLs in North Carolina to identify 
community oncologists who test and those who do not.  When the list is complete, the companies will 
use materials in the professional kit or other materials based on the contents to educate community 
oncologists about the importance and value of molecular testing, focusing first on oncologists who 
already test some of their patients.   
Building on the Change 
In addition to making physician calls, sales representatives and MSLs will invite thought 
leaders and community oncologists who routinely perform molecular testing to be speakers at 
educational events (e.g. Grand Rounds, symposia, teleconferences) with their colleagues.  The 
interviews and literature point out the power of peer-to-peer influence in motivating physicians to 
change their behavior.  Speakers will reinforce the core messaging using materials provided in the 
kit.  Samples of patient materials will be made available to attendees who can bulk order them 
from sales representatives for office use. 
Anchoring Change in the Culture    
 This step generally applies to changing the culture of an organization or company.  
Community oncologists may be members of professional organizations but, in truth, their 
connections with peers are mostly informal and based on the fact they all treat patients with 
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cancer.  Influencing change is difficult even in well-established organizations; influencing 
cultural change in a loosely knit group of individuals is even more difficult (Kotter, 1996).  
Reflexive testing is a way of institutionalizing molecular testing without requiring cultural 
change.  Pathologists and managers of hospital labs can institute protocols for performing 
molecular testing of lung cancer biopsies with certain characteristics.  Reflexive testing ensures 
every eligible tumor sample is tested when a biopsy is done, eliminating the need for individual 
oncologists to order molecular testing. 
Table 5 - Summary of Recommendations 
Action Step Recommendation 
Creating a sense of urgency 
 
Share results of research with professional and advocacy 
organizations, and pharmaceutical companies in NC. Identify 
target audiences. 
Forming a powerful coalition Establish a task force.   
Creating a vision for change 
 
Task force develops vision and mission statements, and 
objectives.   
Communicating the vision Task force develops a comprehensive communications plan, 
including two turnkey kits – one for healthcare professionals 
and one for consumer audiences. 
Overcoming obstacles  
 
Execute audience-specific tactics to motivate change.  Create 
professional and consumer education kits.   
Creating short-term wins  
 
Focus first on community oncologists who already test some 
patients. 
Building on the change Leverage the power of peer-to-peer influence. 
Anchoring change in the 
culture    
Focus on increasing development of institutional protocols for 
reflexive molecular testing. 
 
Influence Map 
The diagram below shows the relationships between influencers and target audiences.  
Each audience is color coded with corresponding colored arrows showing the direction of 
influence.  In many cases, there are multiple influences on important audiences increasing the 
reach and frequency of messaging and the potential for change (Keller). 
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Figure 11 - Influence Map 
 
 
 
 
 
 
 
 
 
 
 
 
Publication and Dissemination of Research and Pilot Results 
 Concurrent with convening the task force, developing the communications plan, and 
executing tactics, I will pursue poster and plenary presentation opportunities at regional and national 
meetings of the American Society of Clinical Oncologists, and the Oncology Nursing Society.  I will 
also be working with Dr. Weiss on developing and submitting a manuscript with the results of my 
dissertation research to peer-reviewed oncology journals for publication.  Once the North Carolina 
pilot is complete, a separate manuscript will be prepared and submitted to journals for publication.   
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Expansion Planning 
 As mentioned, each tactic executed during the pilot will be evaluated based on pre-set 
criteria.  One of ongoing the goals of the task force will be expanding the reach of tactics that most 
successfully increased the use of EGFR testing in North Carolina to regional and national audiences.  
Before the expansion can begin, the task force must raise enough money to fund the outreach effort.  
Having tangible results from the pilot demonstrating the positive impact of the tactics selected for 
expansion will bolster the task force’s request for additional financial support.  Pharmaceutical 
companies and molecular test manufacturers, along with other donors, will be asked to contribute 
money for the expansion efforts.   
 Identifying the best professional and consumer organization partners is another essential 
step in expansion planning.  Task force members will compile a list of potential partners based on 
the ease of working with the various state-level organizations participating in the pilot and their 
individual experience working with partners on other initiatives.  Task force members will take 
advantage of existing relationships with leaders of regional and national level organizations to get 
buy-in and support, and will ask colleagues for help gaining access to other organizations.   
The task force will set new objectives for each expanded tactic and will monitor progress 
toward achievement of objectives on a quarterly basis.  Under-performing tactics will be 
discontinued as quickly as possible to avoid expending resources on tactics not producing desired 
results.   
Conclusion 
 This dissertation was groundbreaking; it provided the first real glimpse into the 
facilitators and barriers motivating community oncologists’ decisions about using EGFR testing.  
As the knowledge about the genetic basis of lung cancer evolves, more genetic mutations have 
been discovered that predict the likelihood a patient will respond to specific targeted therapies.  
Each incremental change in the knowledge about lung cancer genetics brings more challenges 
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but, more importantly, it increases oncologists’ ability to further personalize treatment and 
improve health outcomes for patients with late stage NSCLC.  Laboratory testing manufacturers 
are developing and testing multiplex panels that screen for a number of these mutations, including 
EGFR; adoption of multiplex tests is likely to mirror that of EGFR testing.  Therefore, I will 
recommend that the task force focus on educating and communicating about the complete array 
of molecular tests available for lung cancer patients.   
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APPENDIX A – LITERATURE REVIEW 
Part 1: Understanding Non-Small Cell Lung Cancer and Treatments 
Lung Cancer Facts and Figures 
It is estimated that over 228,000 individuals in the U.S. will be diagnosed with NSCLC in 
2013 (American Cancer Society, 2013) and more than 180,000 of them will have advanced or 
metastatic disease at the time of diagnosis.  Although lung cancer accounts for only 15% of all 
cancer diagnoses each year, it accounts for approximately 28% of cancer-related deaths 
(American Cancer Society, 2013; Silvestri G. A., 2005).   
NSCLC is “staged” according to the severity or extent of disease (National Cancer 
Institute, 2010).  Staging is based on tumor size and extent of cancer spread to other parts of the 
body (metastasis).  There are seven stages of NSCLC ranging from occult (hidden) to stage IV 
(metastatic) (National Cancer Institute, 2010; WebMD, 2005).  Stages II, III, and IV are 
subdivided into A and B depending of the size and location of the tumor(s).  Cancer staging is 
complex and is determined by tissue and blood analysis, diagnostic tests, and imaging; treatment 
approaches vary by cancer stage (National Cancer Institute, 2012).    
Patients with stage I and II NSCLC are potentially curable (also known as operable or 
resectable) (Maghfoor, 2010) with surgery, radiation, laser treatment, chemotherapy, a targeted 
therapy or a combination of two or more of these approaches (American Cancer Society, 2013; 
Giaccone G. , 2007; Maghfoor, 2010).  Approximately 50% of early-stage patients will be alive 
five years after diagnosis.  NSCLC is classified as IIIB if there are malignant cells in the fluid in 
the space between the layers of tissue lining the lung and stage IV if the cancer has spread to the 
other lung or another part of the body.  Life expectancy for patients with stage IIIB or IV is less 
than one year.  As noted, most patients diagnosed with NSCLC are in advanced stages IIIB or IV, 
meaning the cancer has spread beyond the initial tumor site and is considered incurable.     
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Patients with advanced stage NSCLC cancer have a median survival of eight to ten 
months and overall survival of 30% at one year when they are treated with standard 
chemotherapy (Sequist L. B., 2007).  Patients who do not respond to initial (first-line) 
chemotherapy treatment live an average of four to five months after diagnosis and only 11%  live 
longer than one year.  Patients who go on to receive second-line chemotherapy after failure of 
first-line therapy or progression after completion of treatment live an average of seven months 
after they are diagnosed.  Less than 5% of patients with advanced disease are alive at 5 years (Tan 
W. W., 2011).  Only a small percentage of the patients who survive two different rounds of 
treatment go on to receive third-line treatment. There are also several different cell types in lung 
cancer.  Adenocarcinoma, which originates from cells lining the tiny air sacs (alveoli) in the 
lungs, is the most common lung cancer cell type accounting for 35% to 40% of all NSCLC cases.  
Cell type is an important consideration when selecting a cancer treatment because the 
mechanisms of cancer growth and spread vary by cell type; various cancer cell types require 
different treatment approaches.   
Traditional Chemotherapy Treatment for Advanced NSCLC  
Treatments for advanced and metastatic NSCLC are aimed at increasing time to cancer 
progression (progression-free survival or PFS); decreasing tumor size; preserving quality of life and 
performance status (ability to perform activities of daily living); delaying or decreasing symptoms, 
such as shortness of breath; delaying the spread of cancer cells to other locations in the body, 
including the brain and bones; and prolonging survival (American Cancer Society, 2010; Conaway, 
2010; National Cancer Institute, 2011; Stuart, 1999).   
First-line treatment.  Chemotherapy is the standard first-line treatment for advanced 
NSCLC (Gazdar A. , 2010; National Comprehensive Cancer Network, 2012); it is given as a 
single drug or multi-drug combination and is usually administered by intravenous infusion in a 
hospital, oncology clinic, or oncologist’s office.  First-line treatment with platinum-based 
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chemotherapy medications is considered the standard of care for patients with advanced or 
metastatic NSCLC (Gridelli C. M., 2009; National Comprehensive Cancer Network, 2012).  Most 
chemotherapy medications kill normal cells along with cancer cells, and are associated with 
significant adverse drug-related effects (Ardizzoni, 1999; De Marinis, 2008; Grossi, 2009; 
Wisnivesky, 2011).   
The high mortality rate in advanced lung cancer is due primarily to the early spread of 
disease and development of resistance to therapy (Uramoto, 2007).  No treatment is universally 
effective for treating patients with advanced NCSLC cancer.  NSCLC is only moderately 
sensitive to chemotherapy (Maghfoor, 2010).  In most cases, traditional chemotherapy provides a 
temporary respite from cancer progression (Gazdar A. , 2010).  Approximately one-third of 
patients with advanced or metastatic NSCLC have an observable response to standard 
chemotherapy regimens and another 20% have temporary disease stabilization (Cataldo, 2011; 
Gridelli C. M., 2009).  The majority of responses tend to be brief with a median time to cancer 
progression of between three to five months.  Most patients relapse soon after completion of 
treatment and almost 50% percent of patients will be too ill to receive second-line therapy 
because of their rapidly progressing disease (Herbst, 2007; Shepard F. A., 2005; Wang, 2012). 
Second-line treatment.  Second-line therapy is the treatment given after a patient’s 
cancer has progressed during or after first-line treatment.  The goals of second-line treatment are 
amelioration of symptoms, and improvements in quality of life and survival; however, the impact 
of treatment is usually modest (Di Maio, 2010).  Second-line treatment typically consists of a 
single chemotherapy drug not used as part of the patient’s initial treatment (Maione, 2010).   
Patients who derive objective benefit from first-line treatment are more likely than those 
who do not to benefit from second-line treatment (Di Maio, 2010).  Unfortunately, many patients 
with advanced or metastatic NSCLC who receive second-line treatment are near the end of life.  
A retrospective review of patients treated in community settings revealed that more than fifty 
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present of lung cancer patients received chemotherapy in the last month of life, and one in five 
received treatment in the two weeks preceding their death.  Data shows that after failure of 
second-line treatment, patients rarely receive any survival benefit from added therapy and they 
often suffer significant side effects in their final days (Di Maio, 2010; Gawande, 
2010).Oncologists know a majority of their patients with advanced NSCLC are going to die 
within a year of diagnosis (Gawande, 2010); however, over forty percent admit to offering 
treatments that are unlikely to work.  This is partly due to demands made by patients and their 
families for additional treatment and the fact many oncologists, wishing to avoid conflict or loss 
of hope, acquiesce (Hurst, 2005).  Oncologists tend to worry more about being overly pessimistic 
than being overly optimistic (Gawande, 2010).  It is difficult for everyone involved—patients, 
families, and physicians--to admit the fight is over.  Hope remains as long as there are treatments 
that have not yet been tried.  The Internet abounds with media reports of potent new cancer 
treatments and anecdotes of miracle cures, which helps explain the interest patients and families 
have in therapies regardless of their odds of helping, and physicians’ willingness to go along even 
in the face of evidence that further treatment is futile (Di Maio, 2010; Hurst, 2005).   
Recognizing the Limitations of Traditional Treatments for Advanced NSCLC 
 Conventional chemotherapy has improved little in terms of effectiveness in the past three 
decades despite the best efforts of researchers and clinicians to discover new, more effective 
therapies (Breathnach, 2001; Maione, 2010).  One-year mortality rates increased only slightly 
from 35% in the late 1970s to 41% in 2004 (Huff, 2010; Printz, 2010).  According to Nathan 
Pennell, MD, PhD, a lung cancer specialist and assistant professor of medicine at the Cleveland 
Clinic Taussig Cancer Center, “’We've really exhausted the capacity of traditional cytotoxic 
chemotherapy to make a huge difference,' he says, ‘by and large, we've been trying to shift gears 
and go to a more targeted approach as our understanding of lung cancer changes’.” (Huff, 2010). 
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Shifting the Treatment Paradigm to More Personalized Treatment of NSCLC 
Cancer biology and genetics have advanced significantly in the past 30 years as 
researchers have focused attention on understanding the mechanisms of cancer development on a 
cellular level; they have discovered NSCLC is a heterogeneous disease with distinct genetic 
characteristics requiring a range of treatment options instead of the traditional one-size-fits-all 
approach (Huff, 2010; Pennell, 2010; Printz, 2010).   
In 1986, Stanley Cohen, Ph.D., of Vanderbilt University, and Rita Levi-Montralcini, MD, 
an Italian developmental biologist were awarded the Nobel Prize in Physiology or Medicine for 
their understanding of the mechanisms of cell and organ growth, including epidermal growth 
factor (EGF) (Nobelprize.org, 1986).  Their discovery paved the way for the development in the 
early 2000s of a class of anti-cancer drugs known as tyrosine kinase inhibitors (TKIs) or anti-
EGFR drugs that block epidermal growth factor receptors (EGFR) in non-small cell lung cancer 
(Ciardiello, 2008; Dunne, 2008; Erikson, 2008; Herbst, 2007; Pennell, 2010; Printz, 2010).   
The development of TKIs has led to additional discoveries that have greatly expanded the 
understanding of the molecular biology of NSCLC, allowing physicians to begin personalizing lung 
cancer treatment based on the molecular characteristics of a patient’s tumor (Sequist L. V., 2008).   
EGFRs or epidermal growth factor receptors are found in the cell membrane that sits between 
the inside and outside of a cell (Sequist L. B., 2007).  The defect occurs in a region inside the cell 
known as the tyrosine kinase domain (Pennell, 2010).  When tyrosine kinase (TK), a protein inside of 
a cell, binds to the tyrosine kinase receptor it triggers a process that encourages the uncontrolled cell 
growth and proliferation characteristic of aggressive metastatic cancer.      
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Figure 12 - Tyrosine Kinase Stimulates Cell Division and Proliferation 
 (Cancer Research UK, 2012) 
It takes only a small amount of growth factor to stimulate lung cancer cells to proliferate in 
patients who have mutations in the tyrosine kinase domain of the EGFR gene; when the EGFR signal 
stimulating cell growth is blocked by a targeted medication cancer cells begin to die (Pennell, 2010).  
The presence of EGFR mutations identify a subgroup of patients with NSCLC whose tumors are 
“addicted” to EGFR signaling, which makes their tumors much more susceptible to treatment with 
tyrosine kinase inhibitors (Sequist L. V., 2008).  
Figure 13 - Mechanism of Action of Tyrosine Kinase Inhibitors  
 (Cancer Research UK, 2012) 
Targeted Oral Treatments for NSCLC 
Tyrosine kinase inhibitors interfere with cancer cells on a molecular level, as described 
above, leaving normal cells untouched, unlike traditional chemotherapy that kills both cancer 
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cells and healthy cells, which leads to serious and potentially life threatening side effects.  The 
FDA has approved two targeted oral TKI therapies for the treatment of advanced and metastatic 
NSCLC, including gefitinib (brand name Iressa™) in May 2003 (AstraZeneca, 2003) and erlotinib 
(brand name Tarceva®) in November 2004 (Genentech and (osi) oncology, 2011).  In 2010, the 
FDA expanded the use of erlotinib to include maintenance treatment of patients with advanced or 
metastatic non-small cell lung cancer whose disease has not progressed after four cycles of a 
specific type of first-line chemotherapy.  In May 2013, the FDA granted approval for expanded 
use of erlotinib as a first-line treatment for patients with metastatic NSCLC who test positive 
EGFR mutations based on results of a companion diagnostic EGFR test approved at the same 
time (FDA, 2013). 
Although the FDA grants companies the right to market approved drugs for specific uses, 
physicians have the freedom to prescribe any marketed drug for any patient based on their 
professional judgment.   
Figure 14 - Progress to More Personalized Lung Cancer Treatment
 
Gefitinib and erlotinib are similar chemically and were both approved by the FDA for 
second-line treatment; however, gefitinib’s use was subsequently limited by the FDA to a small 
subset of patients after a study showed the drug had no impact on survival or disease-related 
symptoms.  There has never been a head-to-head study comparing gefitinib and erlotinib; however, 
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experts have analyzed a number of independent studies and have concluded that gefitinib and 
erlotinib have comparable benefits (Keedy V. L., 2011); therefore, clinicians believe studies done 
with gefitinib are a reliable proxy for erlotinib.  Because of the limitations placed on the prescribing 
of gefitinib in the US, this paper will focus on erlotinib. 
Treatment with Erlotinib  
The FDA based their approval of erlotinib on results from a single randomized, double blind, 
placebo-controlled trial of 731 patients with locally advanced (stage IIIB) or metastatic NSCLC 
(stage IV) who had failed at least one chemotherapy regimen (Shepard F. A., 2005; Tsao M. S.-R., 
2005).  The response rate with erlotinib was 8.9% compared with less than 1% response (P < 0.001) 
in the placebo group; the median duration of response was 7.9 months and 3.7 months, respectively.  
Rates of complete response (disappearance of all signs of cancer) and partial response (decrease in 
tumor size or extent of cancer in the body) in the erlotinib group were 0.7% and 8.2%.  No patients in 
the placebo group achieved complete response and less than 1% achieved partial response.  Median 
progression-free survival (PFS) (period of no further tumor growth or spread) was 2.2 months with 
erlotinib treatment and 1.8 months with placebo (P < 0.001).  Overall survival in patients receiving 
active treatment was two months longer (6.7 months vs. 4.7 months, p< 0.001) than placebo, which 
was a statistically significant difference.   
 During the analysis of placebo-controlled clinical trials, certain patterns emerged with 
respect to therapeutic response to erlotinib therapy (Lynch, 2004; Paez, 2004; Pao W. M., 2004; 
Shepard F. A., 2005; Shepard F. A., 2005; Tsao M. S.-R., 2005).  Certain clinical and 
demographic characteristics were associated with a higher likelihood of clinical response to 
erlotinib, including female gender, Asian origin, never smoking or light former smoking, 
adenocarcinoma tumor histology, and presence of specific EGFR mutations in tumor tissue.  The 
first three factors listed are phenotypic characteristics that are easily identifiable by observation or 
simple questioning.  They are used by many oncologists to guide treatment decisions even though 
published data shows reliance on non-genetic factors is not enough to accurately predict response 
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to oral TKI treatment (Cataldo, 2011; Gazdar A. , 2010; Lennes, 2011; Maione, 2010; Printz, 
2010; Shepard F. A., 2011; West J. H., 2010; West J. H., 2010).  On the other hand, a biopsy,  
which is an invasive procedure, is required to determine tumor histology (adenocarcinoma) and 
EGFR mutation status, which may influence oncologists to rely on easily observable 
characteristics when making treatment decisions.   
 In April 2010, the FDA approved the expanded use of erlotinib for maintenance treatment 
for patients with advanced or metastatic NSCLC (Genentech, 2010).  The purpose of maintenance 
therapy is to provide continuing treatment for patients who respond or have stable disease after 
initial chemotherapy, which allows for continuing anti-cancer treatment before the cancer has a 
chance to worsen or spread further.  The maintenance indication was approved based on results of 
the SATURN trial, which was an international, randomized, double blind, placebo-controlled 
study of 889 patients with advanced NSCLC.  In this trial, erlotinib when used immediately after 
first-line chemotherapy extended overall the survival (OS) of patients by one month (Genentech, 
Astellas).  Time to cancer progression (PFS) was 2.6 months for patients treated with placebo 
compared with 2.8 months for patient treated with erlotinib.   
National news outlets, along with health care professional and patient web sites and blogs, 
carried the news of the FDA approval for the maintenance indication.  Much of the coverage 
originated from the pharmaceutical manufacturers’ press release, which implied, through use of 
selective statistics, that maintenance treatment with erlotinib leads to major improvements in overall 
and progression-free survival (Genentech, 2010).   
In May 2013, the FDA approved erlotinib for use as first-line treatment of patients with 
metastatic NSCLC who have tested positive for certain EGFR mutations (FDA, 2013).  Several 
prospective studies conducted with patients treated with erlotinib or gefitinib first-line after testing 
positive for an EGFR mutation resulted in significantly better outcomes--with objective response 
rates of 50% or more--as compared with response rates (< 10%) achieved in studies involving 
“unselected” patients who had not been EGFR tested prior to being treated; these studies further 
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demonstrate the utility and benefit of using pretreatment testing to determine the likelihood of 
response to erlotinib. 
A major drawback of treating patients with erlotinib is the cost of the medication.  A single 
month’s supply of erlotinib tablets at a standard dose of 150mg each day is over $5,500, and it may or 
may not be covered by insurance (Drugstore.com) .  Even individuals who have prescription drug 
coverage may face very large out-of-pocket expenses due to high copayment requirements set by 
some payers.  Medicare Part D covers erlotinib; however, due to the coverage gap or “donut hole,” 
seniors without supplemental insurance will incur significant costs in the first month of treatment.  In 
fact, out-of-pocket costs for erlotinib for patients with insurance coverage will usually exceed patient 
costs associated with physician-administered chemotherapy treatments even though one treatment 
with standard chemotherapy is (in most cases) significantly more expensive than a one-month supply 
of erlotinib.  
Even though the adverse effects of erlotinib are generally less serious and debilitating than 
those associated with traditional chemotherapy, the drug is not without side effects, which range from 
bothersome to deadly (Bonomi, 2007; Cataldo, 2011; Dancey, 2007; Silvestri G. A., 2005).  A sizable 
portion of clinical trial participants treated with erlotinib experienced side effects (Dunne, 2008; 
Genentech and (osi) oncology, 2011).  The most frequently occurring reactions included rash 
(49.2%), diarrhea (20.3%), anorexia (9.2%), and fatigue (9%).  Almost 20% of patients required dose 
reductions, treatment interruptions, or discontinuation because of drug-related adverse effects 
compared with 2% of patients treated with placebo (Shepard F. A., 2005).  Five percent of patients 
taking erlotinib discontinued treatment altogether due to drug-related toxicities compared with 2% of 
patients receiving placebo. 
Rash would seem to many to be a relatively benign side effect and a small price to pay to 
delay cancer progression; however, many patients are unable to tolerate the uncomfortable, itchy, 
unsightly, and potentially disfiguring rash, which manifests as severe acne-like symptoms and skin 
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shedding on the scalp, face, and torso (Dunne, 2008; Genentech and (osi) oncology, 2011).  In rare 
cases, deaths have resulted from severe rash.  For many patients, rash is the most distressing part of 
taking erlotinib and there is often little that can be done to provide effective symptom relief.  An 
estimated 60% to 80% of patients in the general population of patients with advanced or metastatic 
NSCLC taking erlotinib (outside of clinical trials) experience rash; it is one of the most common 
reasons for dose reductions and treatment discontinuation.   
Figure 15 - Examples of Skin Reactions Caused by Erlotinib  
 (Genentech, 2010)  (Oteria, 2009) 
In addition to rash, eye problems occur in about one-third of patients treated with erlotinib 
(Dunne, 2008; Genentech and (osi) oncology, 2011).  Eye-related problems include swelling, redness, 
itching, tear dysfunction, crusting along the lash line, and abnormal growth and thickening of 
eyelashes.  Corneal perforation and ulceration caused by eyelash changes can be serious and result in 
severe pain and sensitivity to light.   
Xerosis (dry skin), primarily of the arms and legs affects over one-third of patients being 
treated with erlotinib (Dunne, 2008); extreme dryness can result in extremely painful deep fissuring 
of the skin of the fingers and toes that makes it difficult to perform activities of daily living and 
interferes with sleep.  Changes in hair growth, loss, and texture, and brittle and loose nails are also 
common but are easier to cope with than an overt rash or skin fissures. 
Diarrhea is more common with erlotinib than traditional chemotherapy; it occurs in up to 
75% of patients treated outside of a clinical trial setting.  It can be severe and difficult to manage in 
some patients and can lead to dose reductions or treatment discontinuation.  
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The side effects mentioned above would seem trivial to most people who are not in a position 
to experience them first hand; however, they can significantly affect a patient’s physical and 
emotional well-being, which can lead to social isolation and depression.  Side effects can interfere 
with a patient’s willingness to take medication as prescribed leading to suboptimal dosing and 
treatment outcomes. 
One of the most serious adverse effects associated with erlotinib therapy is interstitial lung 
disease (ILD), which can cause progressive scarring of lung tissue that affects the ability to breathe 
and maintain adequate oxygen levels.  It is very rare, occurring in slightly less than one percent of 
patients (Genentech and (osi) oncology, 2011); however, ILD is usually non-reversible and can be 
fatal.  Other potentially deadly side effects include liver toxicity and renal (kidney) failure (FDA, 
2009; Genentech and (osi) oncology, 2011; Witt, 2008).   
Predicting Responders and Non-Responders to Erlotinib 
The low response rate to erlotinib, high cost of treatment, adverse effects ranging from 
annoying to potentially fatal, and the negative consequences of prescribing a tyrosine kinase 
inhibitor to a non-responder suggest it is important—if not clinically imperative--to prospectively 
identify patients who are likely to benefit from treatment, which can be done through the use of 
molecular testing.  
There are four basic types of molecular markers or test types including diagnostic, 
prognostic, predictive, and companion diagnostic (Febbo, 2011).  Diagnostic markers can confirm 
the presence of a specific disease or classify a disease subtype (e.g. presence or absence of a 
specific gene mutation) based on tests done on tissue or fluids taken from a patient.  Prognostic 
factors predict clinical outcomes (e.g. overall survival) regardless of treatment rendered.  
Predictive markers help clinicians choose from among available treatment options based on their 
likelihood of being successful in a given patient.  A predictive molecular test can confirm the 
presence of an EGFR mutation; it is currently the most reliable predictor of a positive clinical  
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response to erlotinib (Cataldo, 2011; Gazdar A. , 2010; Printz, 2010; Shepard F. A., 2011; West J. 
H., 2010; West J. H., 2010).  Companion diagnostic tests can be diagnostic, prognostic, or 
predictive; they are useful for identifying patients with characteristics associated with positive 
treatment outcomes.   
When a physician suspects a patient has lung cancer based on imaging studies (e.g. x-ray, 
CT scan), a tumor biopsy (tissue sample) is usually obtained to determine if the tumor is 
malignant.  If it is, the tumor cell type (e.g. adenocarcinoma) is identified by viewing cells under 
a microscope.  The biopsy tissue can also undergo molecular testing to determine the presence of 
an EGFR mutation.     
A biopsy involves obtaining a sample of the tumor by inserting a needle through the chest 
wall and into the tumor or fluid surrounding the lung (AstraZeneca; Printz, 2010).  It is an invasive 
process carrying significant risk.  Molecular testing is not an option for patients who do not undergo a 
biopsy or in cases when the tissue volume taken during a biopsy is insufficient for performing 
mutation analysis.   
EGFR molecular testing analyzes the DNA in the EGFR gene located in tumor cells to detect 
genetic mutations.  Known mutations, which sensitize tumor cells to the effects of erlotinib are found 
in four exons of the EGFR gene from exon 19 to 21 (Amler, 2005; Han, 2006; Jackman, 2009; John, 
2009; Sequist L. V., 2008; Tsao M. S.-R., 2005; Yamamoto, 2008); these mutations are associated 
with a positive clinical response to drug therapy.  An exon is a segment of a gene that contains the 
code for synthesis of a specific protein, such as tyrosine kinase (America Heritage Science 
Dictionary, 2005).  Mutations in exons 19 and 21 of the EGFR gene account for 90% of all mutations 
associated with clinical response to tyrosine kinase inhibitors, including erlotinib (Sharma, 2007).  
The specificity of these tests is 100% (Kamel-Reid, 2012) with a sensitivity of 95% (Angulo, 2012).  
Tests yield a “yes” or “no” answer, which means an EGFR mutation is or is not present 
(Gochenhauer, 2012); this makes it easy for oncologists to understand the test results.  
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Figure 16 - Basic Steps in EGFR Mutation Testing
 
As with every medical proceedure, there are challenges associated with using molecular 
testing, including costs of $800 or more for the test and analysis (Association for Value-Based Cancer 
Care, 2012; Levenson, 2008); the need to use tissue extracted during a biopsy instead of a simple 
blood test (Association for Value-Based Cancer Care, 2012; Printz, 2010; West J. H., 2010); the lack 
of consistent  regulatory standards; inconsistency in oversight across laboratories performing the 
tests; lack of definitive evidence that routine testing of all advanced NSCLC patients increases overall 
survival, the risks associated an invasive procedure (biopsy) (West J. H., 2010); and a delay of 5 to 7 
days or longer to receive test results, which could delay the initiation of treatment.  However, it is not 
known at this time if or how often these factors play a role in an oncologist’s decision to forego 
pretreatment molecular testing.  
Despite these challenges, Dr. Mark Kris, a world-renown expert in lung cancer, is a staunch 
advocate of pretreatment molecular testing (Association for Value-Based Cancer Care, 2012; 
National Lung Cancer Partnership, 2012); he believes genetic testing for EGFR mutations in 
advanced lung cancer patients is and should be driving treatment decisions.  He has based his opinion 
on the results of the IPASS (Iressa Pan-Asian Study) and the TORCH (international multicenter 
randomized phase III study of first-line erlotinib followed by second-line cisplatin plus gemcitabine 
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versus first-line followed by second-line erlotinib in advanced non-small cell lung cancer) studies.  
The TORCH study is reviewed in the next section.  
 IPASS was a landmark study that conclusively demonstrated that molecular testing is a 
superior method of identifying patients appropriate for TKI-based treatment as compared with the use 
of clinical characteristics or observations (Gridelli C. B., 2008).  All subjects were Asian, had 
advanced or metastatic adenocarcinoma NSCLC, were either non-smokers or light former smokers, 
and had no prior cancer treatment; they all underwent molecular testing prior to starting treatment.  
Sixty percent of the participants tested positive for EGFR mutations.  The remaining 40% of subjects 
had clinical or demographic characteristics consistent with response to erlotinib or gefitinib, but they 
did not have an EGFR mutation.  
Patients in the study were randomized to receive gefitinib or standard first-line combination 
chemotherapy.  The patients who tested positive for EGFR mutation and treated with gefitinib 
experienced significantly higher response rates and progression-free survival than similar patients 
treated with chemotherapy.  The 40% of study participants who did not have an EGFR mutation had a 
significantly better response rates and progression-free survival with standard chemotherapy than 
similar patients treated with gefitinib.  This study demonstrated clearly that using clinical 
characteristics to make treatment decisions could result in overprescribing of erlotinib to patients who 
would have better outcomes if treated with standard chemotherapy.    
Although a growing body of published research confirms the benefits of prospective 
molecular screening of patients with advanced NSCLC, many oncologists continue treating every 
patient the same, as if NSCLC is a homogeneous disease (Gridelli C. B., 2008).  Oncologists who 
understand individual patients may respond differently to erlotinib most often use clinical 
characteristics to identify the patients they think are likely to respond instead of ordering EGFR tests. 
In fairness to oncologists who do not order EGFR tests for their patients with advanced 
NSCLC, the FDA does not require molecular testing be done as a condition of prescribing erlotinib.  
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However, the two most prominent professional organizations that produce guidelines for cancer 
treatment—the American Society of Clinical Oncology (ASCO) and the National Comprehensive 
Cancer Network (NCCN)--recommend testing, especially for patients being considered for first-line 
treatment with a TKI (American Society of Clinical Oncology, 2011; National Comprehensive 
Cancer Network, 2012).   
ASCO, the world’s largest professional organization of oncologists, in 2011 issued a 
preliminary clinical opinion based on the outcome of five randomized, controlled trials, 
recommending that patients with advanced or metastatic NSCLC undergo EGFR mutation testing to 
determine the most appropriate first-line therapy (Keedy V. L., 2011).
Also in 2011, the NCCN, an alliance of 21 leading cancer institutions in the U.S., issued a 
clinical management guideline recommending EGFR testing be done after a tumor has undergone 
tumor cell-type (histologic) analysis and has been determined to be an adenocarcinoma before 
deciding on a treatment approach (National Comprehensive Cancer Network, 2012).  NCCN also 
recommends patients with advanced or metastatic NSCLC who test positive for EGFR mutation at the 
time of diagnosis receive erlotinib first-line and patients with unknown or negative EGFR mutation 
status be treated with conventional chemotherapy even when patients have clinical characteristics 
suggestive of response to erlotinib, such as female gender, non-smoking history, and Asian race.   
The International Association for the Study of Lung Cancer, the American Thoracic Society, 
and the European Respiratory Society have also gone on record as being in favor of EGFR mutation 
testing of patients with advanced or metastatic adenocarcinoma or non-specified NSCLC (Travis, 
2011).  These groups collectively concluded that EGFR mutation is a validated predictor of response 
and progression-free survival in advanced or metastatic lung cancer patients treated with erlotinib or 
gefitinib. 
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The Consequences of Selecting the Wrong Treatment  
At the time of diagnosis or when NSCLC progresses despite treatment, either immediately or 
after a period of “remission” (progression free survival), oncologists and their patients are faced with 
the question of what to do next.  Treatment options include chemotherapy; erlotinib; crizotinib (brand 
name Xalkori®), which is a relatively new treatment that is effective in the small percent (4%) of 
advanced and metastatic NSCLC patients with a specific mutation in the ALK gene (Pfizer, 2012); 
bevicizumab (Avastin®, Genentech), a monoclonal antibody; or a combination of two or more of 
these treatments (Genentech, 2010; Pfizer, 2012).  They can also choose to stop treatment.  If the 
physician and/or patient are not yet ready to stop treatment, erlotinib is an easy option based on its 
convenience and safely profile compared with standard chemotherapy or other cancer-fighting 
medications given by intravenous infusion.  
However, the results of recent studies indicate the order of treatment—standard 
chemotherapy given as first-line followed by erlotinib second-line or vice versa--matters greatly with 
respect to treatment outcomes (Gandara, 2010; Gridelli C. B., 2008; Lennes, 2011; Printz, 2010; West 
J. H., 2010; West J. H., 2010; West J. H., 2010).  People who have an EGFR mutation making their 
lung cancer more susceptible to erlotinib fare significantly better when treated with the erlotinib first 
instead of chemotherapy; the opposite is true for people who lack the mutation(s) predictive of a 
positive clinical response to oral TKIs.   
In the TORCH study, patients with advanced or metastatic NSCLC were randomly assigned 
to receive first-line treatment with chemotherapy or erlotinib followed by cross-over to the other 
treatment at the time of cancer progression (Brooks, 2012; Gandara, 2010; Gridelli C. B., 2008; West 
J. H., 2010).  Only 55% of patients who started on chemotherapy went on to receive erlotinib and 
fewer than half (49%) of those started on erlotinib crossed-over to chemotherapy because they were 
too sick to receive more treatment.  
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The results of the planned interim analysis showed the outcomes of patients who received 
erlotinib first-line were 40% worse than those who received chemotherapy first and the study was 
stopped for safety reasons.  Patients who received chemotherapy first-line had a 28% response rate vs. 
those who received it second-line (10%) after erlotinib.  The researchers predicted the response rates 
would be similar in the two groups and patients who received erlotinib first could be switched to 
chemotherapy and achieve the same outcome they would have if treated with chemotherapy first, 
which was not the case.  This study made it clear that starting unselected patients on erlotinib instead 
of chemotherapy has serious health and mortality consequences, in addition to financial costs 
associated with purchasing ineffective treatment and unnecessary exposure to adverse drug events.  
The opposite is true as well.  There is a “significant penalty in terms of overall survival” when 
patients with an EGFR mutation are treated with chemotherapy rather than erlotinib (West J. H., 
2010).  People with EGFR mutations often have a sustained period of progression free survival that is 
extremely unlikely to be achieved with traditional chemotherapy.  They die faster when given 
chemotherapy instead of erlotinib. 
Ongoing analyses of the results of the TORCH study have led researchers to conclude 
that only those patients with an EGFR mutation should be treated with erlotinib first-line (Brooks, 
2012; Gandara, 2010; National Lung Cancer Partnership, 2012; West J. H., 2010; West J. H., 
2010).  Patients with unknown or negative EGFR status should be treated initally with 
chemotherapy.  It is very unusual for patients who test negative for EGFR mutations to have a 
meaningful response to erlotinib (1.1%) (Mok, 2009).  Experts believe erlotinib should be 
reserved in these patients until other, more traditional options have been tried because erlotinib is 
likely to cause more harm than good in patients lacking an EGFR mutation.   
The Prevalence of EGFR Testing in the U.S. 
The IPASS and TORCH trials demonstrate clearly that EGFR mutation testing is 
effective in identifying patients who are more likely to derive benefit from erlotinib.  In light of 
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the weight of the evidence, the importance and role of EGFR testing of patients with advanced 
NSCLC is difficult to deny.  However, evidence suggests strongly that most oncologists have not 
yet adopted EGFR testing as a routine part of their clinical practice.   
ASCO believes molecular mutation testing use is widespread at academic medical and 
comprehensive cancer centers and is rarely used in community oncology practices where more 
than 80% of cancer patients are treated (Community Oncology Alliance, 2011; Keedy V. L., 
2011).  This suggests there is significant underutilization of EGFR testing in non-small cell lung 
cancer patients being treated in the U.S.  However, the extent of the problem was unknown until 
late 2011. 
An analysis conducted by Julie Lynch, PhD, at the University of Massachussetts, Boston, 
was presented at a conference sponsored by the American Association of Cancer Research 
(AACR) in fall 2011.  The study, which was the first comprehensive analysis of the use of EGFR 
testing ever published, confirmed EGFR mutation testing is vastly underused by oncologists 
treating lung cancer patients in the US (Alt, 2011; Lynch J. A., 2013).  Dr. Lynch obtained the 
data used in the analysis from Genzyme Corporation, which launched an EGFR diagnostic test in 
2005.  The data represents an estimated 98% of EGFR testing conducted by community hospitals.  
The analysis included only a small amount of data from the 59 National Cancer Institute (NCI) 
designated cancer centers, which are select academic medical centers and comprehensive cancer 
centers recognized for scientific excellence and their range of cancer research approaches.  Most 
NCI designated centers have separate agreements with Genzyme or employ their own assays, so 
their data were not available for evaluation.  Dr. Lynch merged the Genzyme database with data 
from the U.S. Census Bureau, the Centers for Disease Control, The National Institute of 
Standards and Technology, the Centers for Medicare and Medicaid Services, and the NCI to 
create a nationwide map showing the county-by-county use of EGFR testing. 
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In 2010, the over 6,000 acute care hospitals in the U.S. combined ordered 6,056 EGFR 
mutation tests (Alt, 2011; American Hospital Association, 2012; Lynch J. A., 2013).  Independent 
pathology laboratories ordered an additional 527 tests, and independent outpatient oncology 
clinics or oncologists ordered an additional 258 tests.  NCI centers ordered 1,019 of the roughly 
6000 tests, which was not a complete count as noted above.  As a point of reference, over 280,000 
patients are diagnosed with advanced or metastatic NSCLC a year (American Cancer Society, 
2013).  Although reporting from NCI-designated centers was limited, a map created by Dr. Lynch 
revealed that testing was clustered in geographic areas surrounding NCI centers, suggesting it was 
likely the procedures being followed by these institutions were influencing the behavior of 
oncologists in surrounding communities (Alt, 2011; Lynch J. A., 2013), which leaves much of the 
country underserved. 
Figure 17 - Location of National Cancer Institute Designated Cancer Centers  
 (Office of Cancer Centers, 2012) 
The Lynch data showed large regional variations in the use of EGFR testing (Alt, 2011; 
Lynch J. A., 2013).  The top states for EGFR testing were New York (1,024 tests), Florida (496), 
California (352), Pennsylvania (338), Massachusetts (334), Maryland (284), and Illinois (272); 
together, these seven states accounted for more than 50% of EGFR tests performed in 2010.  
States without at least one NCI-designated cancer center had extremely low testing rates.  
However, the presence of an NCI Cancer Center was no guarantee testing was being performed 
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routinely.  For example, only five tests were performed in Utah, the home of the Huntsman 
Cancer Institute, and six were done in New Mexico, the home of the University of New Mexico 
Cancer Center.   
EGFR tests were performed in only 357 (11%) of the 3,124 counties in the U.S.  The 
counties accounting for the highest number of tests included Nassau County, NY; New York 
County, NY; Baltimore County, MD; Kent Country, MI; and Cook County, IL.  Other counties 
with a relatively high number of tests are located in areas surrounding Phoenix, AZ, Boston, MA, 
Miami, FL, and Los Angeles, CA.  Most of these counties have or are close to an NCI-designated 
cancer center.  Counties with the highest incidence of lung cancer had the lowest rate of EGFR 
testing; these counties tended to be rural with low socioeconomic status and relatively poor access 
to health care. 
Based on available data, the use of EGFR testing in treatment selection for patients with 
advanced or metastatic NSCLC is very low (Alt, 2011; Chustecka, 2013; Chustecka, 2013; Lynch 
J. A., 2013).  Several factors may contribute to this low utilization rate.  The cost of tests range 
from $700 to $1000 per test, but the cost is coming down rapidly as laboratories are finding ways 
of reducing expenses and increasing throughput.  However, in comparison to the over $5,500 
monthly cost for erlotinib tablets, the cost of an EGFR test seems to be a reasonable investment.  
There are other challenges associated with testing, such as the need for a biopsy and a 5 to 7-day 
waiting period for test results.     
According to the Lynch data, many oncologists do not order molecular tests even though the 
practice is endorsed by the major organizations responsible for setting guidelines for oncology 
practice in the U.S and publicized widely in medical journals and other medical media.  On paper, the 
choice seems clear, but it is obviously not or EGFR testing would be more widespread.  There are 
obviously barriers to adoption of molecular testing based on the Lynch data, but we do not know for 
sure what those barriers are.  There are also factors influencing and motivating oncologists to use the 
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tests.  Part two of this literature review will focus on facilitators and barriers to adoption of medical 
innovation along with an analysis of the relative success of various methods used to influence 
physician behaviors. 
Part 2: Influencing Physicians' Clinical Behaviors and Decisions   
There is significant and growing interest in the medical community in the burgeoning ability 
to “personalize medicine” to better meet individual patient needs and circumstances, and improve 
quality of health care.  The concept relies on an increasingly sophisticated understanding of the 
genetic basis of disease and response to drug therapy, which allows physicians to tilt the risk-benefit 
balance more strongly in favor of patient benefit by predicting which patients are more likely to gain 
the greatest benefit from a specific therapy while at the same time minimizing associated treatment-
related risks.  EGFR testing has been available in the US since 2005.  However, as noted in part one 
of this chapter, having widespread access to molecular testing, clinical guidelines issued by 
prestigious oncology organizations, and recommendations from well-respected expert thought leaders 
has done little to motivate the majority of oncologists to perform EGFR testing before prescribing 
treatment for specific patients.   
Why is pre-treatment EGFR testing underused?  Lung cancer experts have offered their 
personal opinions, but there are no published data about decision criteria used by oncologists when 
considering whether to perform EGFR testing for their patients with advanced or metastatic NSCLC; 
therefore, we are left to examine facilitators and barriers associated with the uptake of innovations in 
other areas of medical care for clues.  The research component of this project goes a step further by 
asking practicing oncologists about their use of EGFR testing and the criteria they use for making 
decisions about testing patients they care for.    
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Facilitators of Change in Medical Practice 
Concerns about quality of health care are nothing new; however, concerns about health care 
spending are becoming more widespread and urgent as the federal deficit grows and health care costs 
become an increasing large percent of the US gross domestic product (GDP) (Centers for Medicare 
and Medicaid Services, 2012).  Cancer medications—particularly newer targeted therapies-- are 
contributing significantly to rising health care costs; the affordability of cancer medications is an 
increasing concern for patients, providers, and payers.  A recently published analysis of over 4000 
health claims revealed an average health care expenditure of over $125,000 per cancer patient (The 
American Journal of Managed Care, 2012); the majority of costs are associated with outpatient cancer 
services, including medications.  The cost of cancer treatments is rising at a rate of 20% per year, 
which is almost double the projected increase in the cost of other prescription medications (11.4%).  
Scrutiny is growing and the trend is considered by many to be unsustainable.  Expensive targeted 
therapies such as erlotinib bear a large responsibility for the dramatically rising cost of cancer 
treatments.  According to Express Scripts, a pharmacy benefit management company, the cost of 
oncology medications and their administration will rise to $173 billion per year in 2020 (Express 
Scripts Specialty Benefit Services, 2010).   
A wide range of stakeholders, including patients and advocacy groups; health care 
professionals and their professional societies; health systems; payers ranging from private insurers to 
managed care organizations (MCOs) to federal and state governments and agencies; lawmakers and 
regulators; institutes, non-profit and voluntary organizations; and others are working on finding ways 
of improving cancer care quality while containing or reducing costs (Centers for Medicare and 
Medicaid Services, 2012; National Cancer Institute, 2012).   
Although there are many barriers to widespread adoption of EGFR testing in NSCLC, 
there are also many levers for improving quality of cancer care, while containing costs.  This 
section focuses on organizations and initiatives with a realistic potential of influencing 
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oncologists to increase their use of EGFR testing when caring for patients with advanced or 
metastatic NSCLC.  There is also the potential for smaller scale initiatives to influence 
oncologists to order more EGFR tests but due to their limited scope and reach, they will not be 
discussed in here. 
Congress and the Patient Protection and Affordable Care Act.  Although there is 
significant interest in doing a better job of spending health care dollars to improve health care 
quality, efficiency, and health outcomes, the U.S. does not currently use cost effectiveness 
analysis to set health care priorities or evaluate health care expenditures (Farina, 2012).  
However, that is changing because of several new initiatives aimed at increasing health care 
quality and affordability.   
In March 2010, Congress enacted the Patient Protection and Affordable Care Act (P. L. 
111-148), which was amended in the same year by the Health Care and Education Reconciliation 
Act (P. L. 111-152) (Kaiser Family Foundation, 2012).  The Affordable Care Act or ACA was 
intended to be a major driver of comprehensive health care reform in the U.S.  The ACA provides 
significant financial help to individuals with low to moderate incomes to help them afford health 
care coverage; it also requires significant health insurance reforms, such as stipulating minimum 
covered benefits, out-of-pocket limits for covered services, elimination of lifetime benefit caps, 
and discrimination based on pre-existing health conditions. 
The ACA has a number of provisions aimed at reducing or maintaining costs and improving 
the efficiency of the health care system.  The accountable care organization (ACO) is one of the new 
health care delivery models arising from the ACA (Centers for Medicare and Medicaid Services, 
2012; Greenapple, 2012).  An ACO is an integrated network system of health care providers that 
voluntarily agrees to manage all of the health care needs for a defined population (minimum of 5,000 
Medicare beneficiaries) for a specific length of time (minimum of three years) (Centers for Medicare 
and Medicaid Services Center for Medicare and Medicaid Innovation, 2012).  Currently, there are no 
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quality measures associated with cancer treatment delivered by ACOs; however, this is likely to 
change as spending on cancer treatments continues to outpace increases in other health care costs.   
Although benefits of pretreatment EGRF testing have been demonstrated clearly, it has not 
yet been addressed by any of the efforts aimed at reining in health care costs or improving 
affordability of medicines.  Taking advantage of such an opportunity—which is already supported by 
extensive research and expert opinion-- has the potential to garner a “quick win” by helping to 
demonstrate the positive impact of health care reform on cancer patient care, costs, and treatment 
outcomes. 
Comparative effectiveness research.  One major area of interest in health care reform is 
comparative effectiveness research (CER), which evaluates the impact of different treatment options 
for a given condition in a specific patient population to provide evidence of effectiveness, benefits, 
and harms that can be used to make better informed treatment decisions (Agency for Healthcare 
Research and Quality, 2012).  CER will generate evidence-based information allowing patients, 
caregivers, and clinicians to make better-informed and potentially more cost-effective health care 
decisions.  The IPASS and TORCH studies mentioned in part one of chapter two are examples of 
comparative effectiveness research.  The 2009 American Recovery and Reinvestment Act (ARRA) of 
2009 (Pub.L. 111-5), also known as the economic stimulus package, provided $1.1 billion for 
translational and health services research (National Cancer Institute, 2012).  The National Cancer 
Institute received $400 million of that money to fund cancer-related comparative effectiveness 
research; currently, none of these funds is being spent on improving the care of patients with lung 
cancer.   
U.S. Department of Health and Human Services.  The U.S. Department of Health and 
Human Services (DHHS) is the principal federal agency responsible for protecting the health of 
Americans and providing essential human services (U.S. Department of Health and Human Services, 
2012).  By virtue of their Medicare program, DHHS is the nation’s largest insurer.  The DHHS 
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collaborates with states to fund and administrate Medicaid and the State Children’s Health Insurance 
Program (SCHIP), which assist low-income individuals to increase their access to health care services 
(Medicaid.gov, 2012; U.S. Department of Health and Human Services, 2012).   
Twelve agencies make up DHHS, but not all have responsibility or the authority to influence 
the rate of adoption of EGFR testing.  Those that do or may in the future include the Agency for 
Healthcare Research and Quality (AHRQ), Centers for Disease Control (CDC), Centers for Medicare 
and Medicaid (CMS), the Food and Drug Administration (FDA), and the National Institutes of Health 
(NIH). 
Agency for Healthcare Research and Quality.  The Agency for Healthcare Research and 
Quality (AHRQ) has three main focus areas for improving health care delivery, including access to 
care and health outcomes for all Americans; encouraging adoption of evidence-based decision-
making to increase the effectiveness of treatments and improve subsequent health outcomes; and 
improving the effectiveness of health services and reducing unnecessary costs by making the 
transformation of research into clinical practice more efficient (Agency for Healthcare Research and 
Quality, 2012; Agency for Healthcare Quality and Research, 2012).   AHRQ measures success by 
evaluating improvements in health care in terms of enhancements in quality of life and health 
outcomes, reductions in morbidity and mortality, and value generated from health care expenditures.   
The AHRQ Center most relevant to this paper is the Center for Outcomes and Evidence 
(COE).  The COE encourages sustainable systemic change by working with health care providers, 
consumers, payers and policy makers, and motivating them to implement evidence-based practices 
demonstrated to improve quality of care and health outcomes; they also direct and support research on 
appropriate use of medications and provide evidenced-based information about medications and other 
treatment options.  The COE has focused primarily on improving screening techniques to increase 
early detection and diagnosis, and providing educational information to consumers on different types 
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of cancer; however, this could change in the future as a result of rising concerns about the 
affordability and access to expensive cancer treatments.  
Centers for Disease Control.  The Centers for Disease Control’s (CDC) Office of Public 
Health Genomics (OPHG) is responsible for evaluating genomic tests and promoting appropriate use 
of those tests (Office of Public Health Genomics, 2012).  OPHG focuses primarily on promoting 
testing for single gene disorders, such as cystic fibrosis, fragile X syndrome, and sickle cell disease.  
However, they also promote the use of genomic tests to increase the probability a patient “gets the 
right drug at the right time.”  They recommend EGFR mutation analysis be performed on patients 
with advanced or metastatic NSCLC to prospectively predict their response to erlotinib therapy; this 
recommendation was based on an evidence-based systemic review of the analytic validity, clinical 
validity, and utility of the test in specific clinical scenarios (CDC Office of Public Health Genomics, 
2012). 
Centers for Medicare and Medicaid Services.  The Centers for Medicare and Medicaid 
Services (CMS) is the largest single payer of cancer-related health care services in the U.S. (Potetz, 
2009).  Persons ages 65 and over make up about 13% of the U.S. population but account for slightly 
over half of new cancer cases and 65% of lung cancer cases.  In 2004, the National Cancer Institute 
estimated Medicare accounted for 45% of total spending on cancer care in the U.S.  In the same year, 
lung cancer accounted for 20% of Medicare spending on cancer (Beasley, 2012).   
Medicare Part D covers erlotinib, but oncologists must apply for prior approval for individual 
patients before coverage goes into effect (Blue of California, 2012).  Medicare recipients with 
supplemental drug coverage must also meet the requirements of their private insurance carriers; many 
of them require patients to pay a portion of the cost of their erlotinib prescriptions (Centers for 
Medicare and Medicaid Services, 2012).   
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CMS serves as a reference point for private health insurers and other payers; other payers 
usually follow CMS’ lead when establishing their criteria for covering health care services and 
medications, including cancer care (Chernew, 2010; Okon, 2012).  Usually changes in Medicare 
benefits, policies, and requirements influence health care delivery throughout the U.S. (Cassidy, 
2010).  CMS began covering EGFR testing in 2013, which could influence other payers follow suit 
(Centers for Medicare and Medicaid Services, 2012). 
Medicaid, a joint federal - state partnership to provide health care to low income Americans 
meeting strict eligibility requirements, does not require states to provide prescription drug coverage to 
Medicaid recipients; however, all states currently provide coverage of outpatient prescription 
medications (Medicare.gov, 2012).  In most cases, state Medicaid programs cover the cost of 
erlotinib, usually with restrictions; however, they are not required to pay for EGFR testing.   
CMS Center for Medicare and Medicaid Services Innovation Center.  CMS’ Innovation 
Center was established by the ACA to foster change in the way health care is delivered and paid 
for by identifying, developing, supporting and evaluating innovative system-based models for 
health care delivery and funding for Medicare, Medicaid, and SCHIP beneficiaries (CMS Centers 
for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation, 2012).  The 
Center received ten billion dollars in funding for the period of 2010 through 2019 (Reid, 2010); 
they provide grants for innovative projects with a potential for improving the health and health 
care of all Americans, while reducing costs.     
To date, the Innovation Center has awarded one grant that may ultimately motivate more 
oncologists to test patients for EGFR mutations before prescribing treatments.  Innovative 
Oncology Business Solutions, Inc. was awarded a three-year, $20 million grant to fund the 
implementation and testing of the medical home concept by seven community oncology practices 
across the US  The goal of the community oncology medical homes “COME HOME” project is 
to improve the appropriateness and quality of cancer care by coordinating all outpatient oncology 
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care including medication management for patients served by the seven participating community 
oncology practices located in Florida, Georgia, Maine, New Mexico, Ohio, Pennsylvania, and 
Tennessee.  If the oncology practices adopt the practice of performing EGFR testing in patients 
with advanced and metastatic lung cancer, it may also motivate other practices to do so.  
However, it will likely take several years for the results of this project to be published and 
influence cancer care delivered by others. 
Federal Food and Drug Administration.  The Federal Food and Drug Administration (FDA) 
is the federal regulatory agency responsible for protecting the public’s health by assuring the safety 
and efficacy of human medicines and medical devices (U.S. Food and Drug Administration, 2012).  
The FDA Center for Drug Evaluation and Research (CDER) regulates the approval of prescription 
medications.  Another division, the FDA Center for Devices and Radiologic Health (CDRH) is 
responsible for evaluating the applicability and safety of genetic tests and granting approval for 
marketing.    
In recent years, the FDA has approved a number of molecular tests to help oncologists 
identify patients who are more likely to respond to treatment who are more or less likely to respond to 
specific cancer treatments, such as erlotinib.  In other cases, the FDA requires oncologists to test 
patients before a specific cancer therapy is prescribed.   
The FDA continues to raise the bar by approving targeted therapies for use in patients with 
certain types of cancer who harbor genetic mutations making them more likely to respond to the 
specific treatment.  The agency is also becoming more aggressive in approving—and in some case 
requiring--companion diagnostic tests be used to identify patients who are the best candidates for a 
specific medication based on their genetic profile.  One example is the recent approval of erlotinib for 
first-line treatment of patients with metastatic NSCLC who test positive for specific EGFR mutations.  
There are now several molecular tests being used to identify patients who are more likely to respond 
to specific cancer medications.  Even though practicing oncologists can choose in most cases to 
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ignore FDA guidance on testing, it is reasonable to assume increasing payer pressure and mandates 
aimed at reducing costs and improving health outcomes will likely increase use of pretreatment 
molecular testing in cancer patients.    
National Institutes of Health.  The National Institutes of Health (NIH) is the largest single 
source of health research funding in the world (National Institutes of Health, 2012; National Institutes 
of Health, 2012); it is comprised of 27 Institutes and Centers, each having a unique mission and 
research agenda.  The organization’s mission is to use the results of funded research to enhance 
health, reduce morbidity and mortality, and reduce burdens of illness and disability (National 
Institutes of Health, 2011).  In addition to funding research and fostering collaboration between 
researchers and research institutions, NIH also provides web-based health and disease-related 
resources for the public.  NIH member organizations most relevant to this paper include the National 
Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).   
National Cancer Institute of the National Institutes of Health.  The National Cancer 
Institute’s (NCI) ability to affect clinical oncology practice stems from their reputation for 
impartiality, credibility, and funding of basic research and clinical trials designed to translate 
research into practical clinical applications.  NCI research is instrumental in influencing adoption 
of new technologies and disseminating treatment-related findings, albeit at a slow pace in many 
cases. 
The NCI is responsible for coordinating the National Cancer Program, created in 1971 
when President Nixon signed the National Cancer Act declaring “war on cancer” (Kufe, 2003), 
conducting and funding cancer research, training researchers and physicians, and disseminating to 
health care professionals and consumers information about cancer prevention, diagnosis, 
treatment, and control (National Cancer Institute, 2011).  The NCI has 23 Offices, and 11 
Advisory Boards and Groups; the two most relevant to this research, the Clinical Trials 
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Cooperative Group Program and the Office of Cancer Genomics are discussed in more detail 
below.   
In 2011, NCI spent almost $300 million on lung cancer research initiatives, including 
over $25 million on 59 projects aimed at increasing knowledge about EGFR mutations and use of 
EGFR testing (National Cancer Institute; National Cancer Institute).  As of February 2013, there 
are over ten active phase III and IV clinical trials studying the efficacy of tyrosine kinase 
inhibitors, including erlotinib, gefitinib and novel compounds, in the treatment of patients with 
advanced or metastatic NSCLC harboring certain mutations in the EGFR gene (National Cancer 
Institute, 2013).  
In addition to funding research, the NCI also provides a wide range of educational 
information on their web site about specific cancers and treatments, including lung cancer 
(National Cancer Institute, 2013).  In the health care professional information section on NSCLC 
treatment, erlotinib is listed as a treatment option for patients with stage IV (metastatic) NSCLC 
(National Cancer Institute, 2013).  There is also a consumer-oriented targeted cancer therapies 
fact sheet mentioning erlotinib and gefitinib as treatment options for patients with metastatic 
NSCLC (National Cancer Institute, 2012); the fact sheet explains the way these two medications 
inhibit the tyrosine kinase activity of EGFR, but they do not mention molecular testing.  In the 
health care professional section of the web site, NCI recommends oncologists perform 
pretreatment EGFR testing on tumors tissue taken from patients with advanced or metastatic 
NSCLC to help them individualize treatment based on a tumor’s genetic profile and likelihood it 
will respond to treatment (National Cancer Institute, 2013). 
The Clinical Trials Cooperative Group Program (CTCGP) is made up of than 3,000 
institutions and 14,000 investigators funded by the NCI (National Cancer Institute, 2009); more than 
25,000 new patients participate in group-conducted clinical trials each year.  The CTCGP increases 
awareness of and recruitment into NCI supported clinical trials improving the speed of trial 
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enrollment, completion, and publication.  The NCI has and is currently funding a number of clinical 
trials under the auspices of the CTCGP aimed at increasing the understanding and use of EGFR 
testing in clinical practice.   
The NCI Office of Cancer Genomics (OCG) has a growing emphasis and commitment to 
increasing research and integration of genomics into clinical oncology practice (Patlak, 2011).  The 
OCG aims to increase understanding of cancer at the molecular level with the goal of improving 
cancer care and health outcomes, and turning genomic information into therapeutic strategies for 
individual patients (National Cancer Institute Office of Cancer Genomics; National Cancer Institute 
Office of Genomic Research, 2012).  They have done work in lung cancer; however, it has not been 
specific to non-small cell lung cancer or EGFR testing.  
National Human Genome Research Institute of the National Institutes of Health.  The 
National Human Genome Research Institute (NHRGI), originally known as the National Center for 
Human Genome Research (NCHGR) was founded in 1989, by the NIH, in collaboration with the U.S. 
Department of Energy, to fulfill the NIH’s role in the International Human Genome Project (HGP) 
(National Human Genome Research Institute, 2012).  The human genome-mapping project started in 
1990 and was completed in 2000.  The map served as a foundation for many important medical 
discoveries in the past decade, including research that has provided an increasingly sophisticated 
understanding of the molecular basis of lung cancer and contributed to the development of targeted 
cancer therapies.   
The NHGRI established the Cancer Genetics Group (CGB), which is comprised of eight 
groups or units responsible for researching various aspects of cancer genetics; these groups are 
responsible for contributing to the discovery and understanding of genes associated with cancer 
susceptibility and progression (National Human Genome Research Institute, 2012).  The Varmus 
Group, which is part of the CGB, is focusing on models of human cancers, particularly lung 
adenocarcinomas and the development of targeted therapies; the group has contributed 
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significantly to the understanding of the role of EGFR in development of lung cancer and 
development of targeted lung cancer treatments.   
Institute of Medicine.  The Institute of Medicine (IOM) is part of the National Academy 
of Sciences (Institute of Medicine, 2012).  It is an independent nonprofit nongovernmental 
organization providing unbiased guidance and evidence on health, health care, and medicine to 
policymakers, decision-makers, and the public.  Much of their work is at the behest of Congress, 
federal agencies, and independent organizations.  The IOM sponsors the National Cancer Policy 
Forum that brings together thought leaders from the cancer community to focus on cancer policy 
issues (Institute of Medicine, 2012).  While Forum members are interested in increasing diffusion 
of innovation in cancer care to enhance quality, they generally do not focus on interventions 
specific to particular cancers or cancer treatments. 
While none of the various government initiatives reviewed here apply directly to 
increasing the use of pretreatment EGFR testing, they demonstrate willingness to address issues 
of quality and affordability of health care.  Given the large amount of federal funds being 
allocated to cancer treatment, it is likely increasing attention and effort will be placed on 
influencing and motivating appropriate drug selection based on molecular technologies that can 
identify the most appropriate treatment(s) for individual cancer patients.   
Lung Cancer Mutation Consortium and the Biomarkers Consortium.  The identification 
of biomarkers is an essential element in the quest for more personalized medicine.  The National 
Lung Cancer Partnership (NLCP) is a lung cancer advocacy group consisting of researchers, health 
care professionals, patients, and patient advocates (The Lung Cancer Mutation Consortium, 2012).  
The NLCP sponsors the Lung Cancer Mutation Consortium (LCMC), which is voluntary group of 16 
cancer centers across the US dedicated to prospectively examining NSCLC tumors, and matching 
patients to the best possible therapies based on molecular testing results.  The organization’s primary 
goal is to “provide the most up-to-date care for lung cancer patients, while collecting valuable 
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information about the frequency and characteristics of abnormalities found in lung tumors to further 
improve patient care.”  Initial funding for the Consortium were made available to the NCI through the 
American Recovery and Reinvestment Act; the funding has now expired and the LCMC is raising 
funds from the private sector (Lung Cancer Mutation Consortium, 2012).   
The Consortium began offering free EGFR mutation testing for NSCLC patients nationwide 
through a study being conducted by 14 of its participating clinical sites until initial funding from the 
federal government expired in 2011 (Lung Cancer Foundation of America, 2010; Lung Cancer 
Mutation Consortium, 2012).  The study reopened in August 2012 using funds donated by individuals 
and corporations.   
In addition to increasing access to EGFR testing through participating sites, LCMC has 
initiated a nationwide campaign aimed at health care professionals, and lung cancer patients and their 
families to increase awareness of the availability of EGFR testing and the critical role it plays in 
treatment selection. 
A second group, the Biomarkers Consortium is a public-private partnership founded by the 
FDA, NIH, and pharmaceutical companies (Farina, 2012).  The organization is seeking to accelerate 
the development and dissemination of technologies, medicines and therapies for treatment of disease, 
including cancer (Biomarkers Consortium, 2012).  They are working to qualify new and existing 
technologies that are useful in predicting drug response or improving clinical practice, and making the 
results broadly available to the scientific community.  Although they are focusing on developing 
outcome measures for lymphoma and lung cancer, their research focus does not currently include 
molecular testing for lung cancer (The Biomarkers Consortium, 2012). 
Patient advocacy organizations.  There are a number of patient advocacy groups working 
on improving health outcomes and access to lung cancer treatment, and reducing deaths from the 
disease; the Lung Cancer Foundation of America (LCFA), the National Lung Cancer Partnership 
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(NLCP), the American Cancer Society (ACS), and the American Lung Association (ALA) are among 
the most prominent groups (Genentech and Astellas Oncology, 2012).  The LCFA provides research 
grants and supports use of molecular testing of people diagnosed with NSCLC; the organization uses 
its web site, publications, and events to encourage patients to be tested.  The ACS and ALA focus on 
primary prevention, increasing early detection, and providing educational information for the lay 
public and epidemiologic statistics for researchers.  The NLCP is the only organization with a formal 
ongoing campaign to increase EGFR testing of lung cancer patients; as mentioned above, the 
campaign is being conducted in collaboration with the Lung Cancer Mutation Consortium (National 
Lung Cancer Partnership, 2012). 
Health care professional associations.  There are a number of non-profit organizations 
representing health care professionals dedicated to improving cancer patient care and treatments; 
among the more prominent are the American Society of Clinical Oncology (ASCO); Community 
Oncology Alliance (COA); Oncology Nursing Society (ONS); and the American Association for 
Cancer Research (AACR).   
With over 30,000 members, ASCO is the second largest organization representing cancer 
care specialists and researchers in the U.S. (American Society of Clinical Oncology, 2012); they are 
“committed to conquering cancer through research, education, prevention, and delivery of high 
quality patient care.”  ASCO is the preeminent physician organization in the oncology field (self-
reported).  In their recently published report, Accelerating Progress Against Cancer: ASCO’s 
Blueprint for Transforming Clinical and Translational Cancer Research, ASCO shares its ten-year 
vision for making cancer research and care significantly more personalized, efficient, and effective 
(American Society of Clinical Oncology, 2012).   
ASCO is one of two major organizations that promulgate clinical practice guidelines 
outlining appropriate methods of treatments and patient care.  The other organization is the National 
Comprehensive Cancer Network (NCCN), which is a non-profit alliance of 21 major U.S.-based 
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cancer centers dedicated to improving the quality, effectiveness, and efficiency of oncology practice 
to improve the lives of cancer patients (American Society of Clinical Oncology, 2012).  Both 
organizations promote the importance of continuous quality improvement in cancer care and the 
development and dissemination of clinical practice guidelines for use by health care professionals, 
other health care decision-makers, patients, and the public.   
The COA is the only professional organization dedicated solely to supporting community 
oncology practice (Community Oncology Alliance, 2012); its primary focus is lobbying Congress to 
increase reimbursement rates for office-based oncology care and treatment. 
The ONS is the largest organization of oncology professionals in the U.S. (and the world) 
with over 35,000 members from oncology nursing and other allied health professions (Oncology 
Nursing Society, 2012).  ONS is dedicated to excellence in patient care, research, education, and 
nursing administration.  Their focus is on finding and sharing practical ways of enhancing care of 
people with cancer rather than on drug treatment. 
The AACR is the oldest and largest oncology research organization in the world 
(American Association for Cancer Research, 2012).  With over 34,000 members throughout the 
world, including translational and clinical researchers, health care professionals, and cancer 
patients and advocates, AACR fosters and supports research in cancer and biomedical science and 
accelerates dissemination of new research findings in scientific and medical communities.  The 
AACR funds a number of research fellowships and grants in lung cancer research; none focuses 
currently on the role of EGFR mutations in predicting treatment outcomes.  There have been a 
number of studies presented on this subject at AACR meetings over the past eight years; 
however, there is currently no organized effort to encourage use of EGFR testing in routine 
clinical practice.   
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Managed care organizations.  Managed care organizations (MCO) play a combination 
role of health insurer, health care delivery, and administration; their primary purpose is reducing 
unnecessary health care costs without compromising quality (Medline Plus, 2012).  They provide 
comprehensive health services to plan enrollees for a contracted per member monthly fee.   
MCOs use a number of different strategies for reducing health care costs including 
providing economic incentives to physicians and patients for choosing less costly treatment 
options; requiring prior authorization of a medication or service to justify the medical necessity 
before providing it to a patient; increasing beneficiary cost sharing for non-preferred medications; 
placing controls on hospital admissions and lengths of stay; providing incentives for selecting 
outpatient vs. inpatient services; assigning case managers for high risk patients and those with 
complex conditions; and aggressively contracting provider rates (American Medical Association 
Council on Medical Service, 2004).   
In 2011, 210 million Americans—including over 11 million covered by Medicare and 
over 39 million covered by Medicaid--were covered by managed care plans (Centers for 
Medicare and Medicaid Services, 2012; MCOL; The Henry J. Kaiser Family Foundation).  The 
largest purchasers of managed care services are employers and the Centers for Medicare and 
Medicaid Services.  Fifty-five percent of Americans have employer-based health insurance and 
90% of those individuals are enrolled in managed care plans (U.S. Census Bureau, 2012). 
It is estimated the value of the targeted cancer drug market will increase to $51 billion in 
2015 (Gochenhauer, 2012).  With the cost of cancer medications growing at 20% or more per 
year, payers are increasing efforts to curtail costs without reducing quality of care (The American 
Journal of Managed Care, 2012; Snyder, 2012).  A recent survey revealed managed care 
administrators believe almost one-quarter of current cancer care costs can be eliminated without 
compromising health outcomes; over eighty percent also believe inappropriate use of medications 
is a major driver of excess costs.  Oncologists and MCO administrators anticipate a significant 
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increase in the aggressiveness of payer plans over the coming years in an attempt to reign in 
medication costs (The American Journal of Managed Care, 2012).   
Requiring physicians to obtain prior authorization (PA) from the health plan before 
prescribing certain high cost medications is the most common lever used by managed care 
organizations to control costs of cancer care and reduce inappropriate prescribing (Farina K. , 
2012; The American Journal of Managed Care, 2012).  Prior authorization requirements are based 
most often on treatment recommendations found in recognized drug compendia, such as the 
American Society of Clinical Oncology and the National Comprehensive Cancer Network 
treatment guidelines.  Although prior authorization requirements can decrease spending on 
oncology medications, their true impact on overall cost of medical care and clinical outcomes is 
unclear (Fischer, 2004; Hamel, 2004; Holcombe, 2011; MacKinnon, 2001).There is conflicting 
information about the percentage of MCOs requiring oncologists to perform biomarker testing as 
a condition for prior approval for coverage of oral oncology agents (Gochenhauer, 2012; The 
Zitter Group, 2012).  In the 2011, respondents to the Kantar Health Oncology Market Access U.S. 
Oncologist Survey involving more than half of the community and hospital-based oncologists in 
the U.S. reported the three largest health plans in their area required biomarker testing as part of 
the prior approval requirements for coverage of erlotinib and gefitinib (Gochenhauer, 2012).  
However, a survey of 450 health plan directors conducted by the Zitter Group in the same year 
indicated very few of the plans surveyed required pretreatment EGFR testing as a condition of 
paying for erlotinib therapy, which is consistent with the Lynch data presented in part one of 
chapter two (Alt, 2011; Lynch J. A., 2013; The Zitter Group, 2012).  Predictably, plans claimed 
their prior approval requirements for erlotinib are less about cost containment and more about 
limiting inappropriate prescribing.  However, given the fact EGFR testing is the best method 
available currently for identifying patients likely to benefit from erlotinib and few payers require 
it as a condition of prior approval, it is reasonable to assume, despite the assertions of managed 
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care administrator, the primary driver behind prior approval requirements at the moment is cost 
control rather than quality.    
Based on the same survey by the Zitter Group, lack of testing requirements for erlotinib 
prescribing may soon be outdated.  Over 70% of plan directors expect to implement prior 
authorization guidelines requiring use of biomarker testing as a condition of coverage of certain 
targeted cancer medications in the coming years (Gochenhauer, 2012).  Because health plans cover 
the vast majority of Americans, their failure to require and/or provide coverage for EGFR testing is a 
major barrier to use of molecular tests.  However, MCOs can increase use of pretreatment EGFR 
testing by adding it to the prior authorization requirements for covering erlotinib (Aspinall, 2007).   
Changing Clinical Practice  
Intellectually, most cost-effective advances in health care make sense and one could logically 
assume they will be assimilated rapidly into routine clinical practice.  However, this is usually not the 
case (Freemantle, 1995; Fuchs, 2011; Oxman, 1995).  The traditional “trial and error” method of 
diagnosing and treating disease has been passed down from generation to generation of physicians 
leading many to reject more prescriptive approaches that impinge on a physician’s clinical autonomy 
and judgment (Aspinall, 2007).  Translation of research into clinical practice is anything but assured 
(Grimshaw J. M., 2012).  It takes an average of 17 years for even the most important medical 
advances documented in the clinical literature to be integrated widely into clinical practice; in fact, in 
most cases adoption remains spotty for almost two decades after introduction of an innovation 
(Institute of Medicine, 2001).   
Under-treatment and overtreatment of disease are common.  Evidence suggests between 20 to 
30% of patients in the U.S. receive care that is not needed or is potentially harmful leading to poor 
health outcomes, unnecessary expense, and higher mortality (Grimshaw J. M., 2012; Institute of 
Medicine, 2001; Rowland, 2004; Schuster, 2005).  It is certainly true in the case of patients with 
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advanced or metastatic NSCLC; failure to test patients for genetic mutations before selecting from 
among available treatment options has serious consequences for patients and society in terms of 
morbidity, mortality, and cost. 
Information Management 
Information management is one of the primary barriers and contributors to slow adoption of 
medical technologies (Grimshaw J. M., 2012).  The tremendous volume of clinical literature 
published each year makes keeping up with the latest findings a daunting task, especially for 
clinicians trying to balance busy practices and personal lives.   
In addition to being targets of medical literature, physicians, like everyone else are being 
bombarded with non-scientific medical information and communications aimed at the public.  As 
mentioned previously, news about cancer treatments is often exaggerated by lay media, which 
can lead consumers (health care professionals and patients) to believe study results are applicable 
to all patients.  Unfortunately, the first publication of medical findings tends to show a more 
dramatic treatment effect than can be expected from use of a treatment in a broader patient 
population because strict study inclusion and exclusion criteria limit participation to a highly 
selected patient population that may have little in common with other patients with the same 
disease.  Even when study results are published in major highly respected peer reviewed medical 
journals, they can be proven false or exaggerated over time as data from other studies 
accumulates, which points to a major drawback of changing clinical practice based on early 
published results.   
Individual studies of interventions aimed at improving quality of medical care rarely 
provide sufficient evidence to motivate physicians to change their behavior (Dornbusch, 2006; 
Green, 2007).  However, there are instances in the oncology world where early observational 
research has led to rapid, large-scale implementation of new treatments before clinical benefit 
was demonstrated in a less rigorously selected population of patients.  One example is a decade-
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long very public battle over use of autologous bone marrow transplant (ABMT) for the treatment 
of breast cancer resulting from publication of early clinical data showing promising results that 
drove early and rapid adoption of the treatment approach.   
In 1988, an article in the Annals of Internal Medicine suggested that ABMT, which is a 
very involved, dangerous, and expensive procedure, was an effective treatment for advanced and 
metastatic breast cancer (Antman, 1988).  The publication reviewed 27 separate studies involving 
17 women; the reported response rate, defined as tumor shrinkage of greater than 50%, was 58%.  
There were no controls in any of the studies.  In early 1989, the Annals published a review of 
results from another 159 women who had undergone ABMT (Cheson, 1989); there was an 80% 
response rate in these patients.  Even though the authors of these two papers cautioned readers 
about the need to conduct randomized controlled trials, they concluded ABMT was superior to 
the best available therapies.  There was no corroborating proof the procedure was effective but 
the media showed no restraint when reporting results; among the publications reporting results 
without caveats were the Journal of the National Cancer Institute (Mahaney, 1989) and the Los 
Angeles Times (Maugh, 1990).   
In December 1989, the Washington Post reported the results of a 20 woman study 
conducted by Johns Hopkins University “a partial success” and went on to note ABMT cost 
$75,000 to $100,000, but insurers and Medicaid usually—but not always—covered the cost 
(Squires, 1989).  That article, along with other positive media reports, articles in medical 
publications, breast cancer advocacy group lobbying, and the personal agendas of a small number 
of fraudulent oncologists led to a presumption of treatment effectiveness, which touched off a 
firestorm in the media, courts, Congress, and medical circles over the refusal of insurance 
companies to pay for “experimental” therapies (Welch, 2002).   
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The tide turned on ABMT a decade later at the widely attended 1999 annual meeting of 
ASCO, with the presentation of the outcomes of four randomized controlled trials disproving the 
value of ABMT as a breast cancer treatment.  A subsequent editorial in the New England of  
Journal Medicine declared the treatment ineffective and unproven, and recommended it be 
abandoned in favor of more promising experimental treatments (Lippman, 2000).  The results of 
these studies were reported widely in the popular press and used by insurance companies—once 
forced to pay for the unproven treatment—to deny claims.  Unfortunately, poor clinical judgment 
and massive public pressure led to over 42,000 unnecessary and dangerous procedures at an 
average cost of $80,000 per person (Mello, 2001).  The case outlined above serves as an ongoing 
reminder to oncologists (and other medical professionals) of the dangers associated with rapid 
adoption of unproven treatment modalities.  One of the mechanisms used to reduce the risk of 
early adoption of questionable or unproven treatments is publication of clinical practice 
guidelines.   
Clinical Practice Guidelines  
 
Clinical practice guidelines (CPGs) are systematically developed statements applying to 
specific diseases, treatments, or clinical conditions or situations created by clinical experts after 
rigorous analysis of the best available clinical research evidence.  CPGs guide appropriate patient care 
and help health care professionals and patients make better-informed treatment decisions (Browman, 
2005; Cabana M. D., 1999; Field, 1990; Field, 1992; Wong R. K., 2012).   
As mentioned earlier, two highly respected and influential professional organizations—
ASCO and NCCN--promulgate lung cancer treatment guidelines, which include recommendations for 
pretreatment EGFR molecular testing of tumors of patients with advanced or metastatic NSCLC 
(American Society of Clinical Oncology, 2011; Browman, 2005; National Comprehensive Cancer 
Network, 2012).  Both organizations include clinical experts on their guideline development teams, 
but vary in their conformity to other characteristics considered essential to development of 
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trustworthy guidelines (Browman, 2005), which could theoretically influence the rate of guideline 
adoption.  The ASCO process is more explicit in how evidence is analyzed and interpreted to satisfy 
the due diligence requirements of an evidence-based approach; NCCN relies more heavily on the 
implicit knowledge and judgment of the clinical experts on the panel.   
ASCO guidelines.  In 2011, ASCO published a Provisional Clinical Opinion (PCO) on EGFR 
testing in NSCLC updating recommendations made previously in the ASCO Clinical Practice 
Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (American Society of 
Clinical Oncology, 2011).  The PCO recommends testing all stage IV NSCLC patients for the 
presence of EGFR mutation before prescribing erlotinib (American Society of Clinical Oncology, 
2011).   
NCCN guidelines.  In addition to issuing treatment guidelines recommending pretreatment 
EGFR testing of patients with advanced or metastatic NSCLC, NCCN established a task force to help 
educate the oncology community about the terminology associated with genetic tumor markers.  They 
also provide information about the current state of biomarker validation in glioma, breast cancer, 
colon cancer, lung cancer, prostate cancer, and acute myelogenous leukemia (Febbo, 2011).  The task 
force report: “Evaluating the clinical utility of tumor markers in oncology,” is intended to help 
oncologists understand the science and technology behind using molecular testing when diagnosing 
and treating these six different types of cancer.     
Clinical Practice Guideline Implementation 
 Theoretically, guidelines should improve quality of care by decreasing deviation from 
accepted standards of care (Cruz-Correa, 2001); however, improvements in quality depend on 
guidelines being applied consistently in medical practice and, in most cases, there is a distinct gap 
between published guidelines and actual clinical practice (Browman, 2005; Roila, 2004).  Even 
though physicians bear responsibility for providing care that is consistent with local and national 
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standards, there are several barriers to implementing guidelines (The Italian Group for Antiemetic 
Research, 1998).  They include awareness, individual knowledge and ability to correctly interpret 
available evidence, clinical experience, respect for clinical experts involved in guideline 
development, the willingness to change and time it takes practitioners to integrate guidelines into their 
individual practice styles, self-efficacy or belief the physician can successfully apply the guideline 
when caring for patients, and personal aversion to practicing “cookbook” medicine (Cabana M. D., 
1998; Cabana M. D., 1999; Kaisser, 2005; Wong R. K., 2012).   
It is important to recognize and understand the gap between published guidelines and current 
practice patterns, so the variation can be taken into account when planning guideline implementation.  
Unfortunately, while there are widely accepted processes for creating strong, evidence-based 
guidelines, there is no standard or proven approach guaranteeing successful guideline 
implementation. 
The Cochrane Effective Practice and Organization of Care (EPOC) group has studied 
common strategies for motivating clinicians to adopt clinical practice guidelines.  Interventions 
studied include printed education materials; medical education meetings; educational outreach visits; 
opinion leaders; audit and feedback; reminders; and financial incentives.  The purpose of the research 
was to determine which of the dissemination and implementation approaches is most effective 
(Francke, 2008; Grimshaw J. M., 2004; Medves, 2010; Wong R. K., 2012).   
Technology-Related Constraints 
Later in this chapter, various interventions shown to be more or less effective in motivating 
physicians to change the way they practice medicine are reviewed.  First, however, it is important to 
consider two intertwined technology-related barriers unique to genomic testing technologies; they 
likely play a role in physician and patient perception of and willingness to use molecular testing; they 
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include lack of genomics knowledge and education, and concerns about medical privacy and genetic 
discrimination. 
Genomics knowledge and education.  Recent genomic discoveries have increased 
dramatically the understanding of the genetic basis of disease, including cancers, by revealing 
complexities hidden in the human genome (Feero, 2011).  The early stage of the genomics revolution 
from 1990 through today has yielded more clinically important advances than any period of discovery 
in western medicine (Feero, 2011; Lander, 2011).  In 1990, the genetic basis was known for 
approximately 2% of over 7,000 inherited conditions resulting from changes in the DNA of a single 
gene; today, the molecular basis is known for over 40% of these conditions, which is a 20-fold 
increase in a little over twenty years.  Other diseases, such as cancers, have more a complex 
molecular basis resulting from inheriting DNA from involvement of more than one gene, spontaneous 
mutations, environmental influences, or a combination of factors.   
Applying advanced technologies and discoveries made in the study of more complex 
diseases, such as cancer, heart disease, and diabetes, have led to significant improvements in 
understanding of the genetic basis of these common conditions, which, in turn, has led to changes in 
the approach to characterizing and treating conditions once thought to be homogeneous diseases 
(Manolio, 2010).  Over one thousand genetic variations have been shown to be associated with more 
complex conditions, with many being previously unknown or unsuspected biological causes 
(Aspinall, 2007; Feero, 2011).  Unfortunately, these discoveries have not led to significant changes in 
the way most physicians diagnose and treat patients. 
One major factor to contributing to the delay in adoption of genomic technologies is the need 
for physicians to have a better understanding of genomics and the implications for their clinical 
practice, along with the knowledge needed to communicate effectively with their patients (Feero, 
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2011).  The Human Genome Project (HGP) was the first and most public effort to expand the 
understanding of the genetic basis of disease (Collins, 1997).   
Dr. Francis Collins, former director of the National Human Genome Research Institute 
(NHGRI), is a leading proponent of finding and implementing practical applications of the knowledge 
gained from mapping the human genome.  Even before the human genome map was completed and 
published in 2003, Dr. Collins identified education as one of the most important elements in 
transforming the knowledge gained from the HGP into clinical benefits for patients.  Physicians need 
to understand the role of genomics, the implications of test results, how genomics can be used to 
improve quality of care and clinical outcomes, and be able to communicate clearly to patients the 
limitations, risks, and benefits associated with genetic testing. 
Results from a recent landmark study of 800 U.S.-based practicing physicians indicate 80% 
of physicians believe personalized medicine will influence their medical practice; however, most 
admitted their current knowledge and understanding of genomics is lacking (CAHG, 2011).  In fact,  
only 30% of oncologists surveyed said they are “very familiar with current issues and advances in 
personalized medicine.”  A majority of physicians surveyed have “low confidence in their ability to 
use and apply molecular diagnostics testing within their practice.”   
In addition to physicians’ self-professed gaps in understanding of genomics, a survey of 
1,000 Americans revealed the U.S. public is skeptical of physicians’ knowledge and capability of 
using genetic information to understand and optimize their health (Cogent Research, 2011).  Fewer 
than one in five (17%)  Americans believe their physician is up-to-date and sufficiently 
knowledgeable about genomics-based medicine.  A slightly higher percentage (21%) believes their 
physician is capable of explaining genomics-based medicine in a way that is understandable. 
Genetic privacy and concerns about genetic discrimination.  Another genomic-specific 
issue raising concerns for both physicians and patients is medical privacy and the potential impact of 
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genomic testing on employability and insurability.  In May 2009, the Genetic Information Non-
Discrimination Act (H.R. 493), also known as GINA, became law (National Human Genome 
Research Institute, 2012); it prevents employers and insurers from discriminating against individuals 
based on the results of genetic tests.  However, these protections do not apply to Tricare military 
health plan participants, the Veteran’s Administration, the Indian Health Service, or individuals 
covered by federal employee health benefit plans (GINAhelp.org, 2010).   
Although policy and patient advocates believed passage of GINA would ease the fear of 
genetic discrimination, physicians and their patients remain concerned (Genetics Home Reference, 
U.S. National Library of Medicine , 2012).  Over 90% of physicians who responded to a recent 
Cogent study expressed concerns about potential misuse of test results by insurance companies and 
60% are worried about the possible impact on patient employment (Cogent Research, 2011).  Patient 
anecdotes about experiencing discrimination based on genetic information abound, which further 
undermines the belief the benefits of testing outweigh the risks; according to the Equal Employment 
Opportunity Commission report for 2011, there were 245 genetic discrimination reports filed and 
monetary awards averaged $500,000 (Equal Employment Opportunity Commission).   
Practically speaking, EGFR testing determines a patient’s likelihood of responding to 
treatment and does not predict a person’s likelihood of developing lung cancer.  These tests do 
not yield information that can be used as a source of discrimination; however, people may not 
understand the distinction or believe this type of testing is different from diagnostic testing.  By 
the time the molecular test is done, insurers already know the patient has lung cancer based on 
medical claims filed previously; the test provides no additional disease-related information that 
can be used to discriminate against the patient.  It is conceivable however, based on current 
clinical practice guidelines, an employer or insurer could deny coverage for erlotinib if a patient 
does not have an EGFR mutation that makes them likely to benefit from the medication.    
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Influencing the Clinical Behaviors of Physicians: What Works and What Does Not? 
Efforts aimed at changing physician behavior can range from simple and relatively low 
cost to very time-consuming, complex, and prohibitively expensive.  This section outlines a 
number of strategies and tactics aimed at motivating physicians to change their clinical practice 
behaviors.  Unfortunately, few have proven successful and, in most cases, the magnitude of 
change has been small.  When possible, information relating to interventions used specifically to 
influence oncologists has been included.   
As of August 2011, the EPOC had evaluated over 7,000 randomized and quasi-
experimental studies in more than 80 systematic reviews of professional, organizational, 
financial, and regulatory interventions.  They identified over 300 systematic reviews of behavior 
change strategies used to influence physicians, which they have synthesized into a small number 
of major categories including printed educational materials; educational meetings; educational 
outreach; local opinion leaders; audit and feedback; reminders, and financial incentives 
(Cochrane Effective Practice and Organisation of Care Group, 2012; Grimshaw J. M., 2012).  
Additionally, there are hundreds of published studies not included in EPOC reviews because they 
did not meet the stringent inclusion criteria.   
Interventions can be one-size-fits-all, tailored, or multi-faceted.  Unfortunately, very few 
studies compare specific interventions to other interventions, so it is often difficult to determine 
the presence of affect or the size of the effect on physician behaviors and clinical outcomes.  One 
truth emerging from the literature is change is more easily driven and sustainable when the 
behavioral targets of change are simple rather than more involved or complex (Satterlee, 2008). 
Printed education materials.  Disseminating scientific information and clinical practice 
guidelines in print is a popular method of communicating scientific information to physicians.  
Printed materials have a self-life and can be read at a person’s convenience, referred to in the 
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future, and passed along to colleagues (Giguère A. L.-K., 2012); in general, printed materials are 
intended to address specific knowledge or skill gaps of physicians (Grimshaw J. M., 2012).  
Printed materials, defined by EPOC as “distribution of published or printed recommendations for 
clinical care, including clinical practice guidelines”, are intended to increase health care 
professionals’ awareness, knowledge, attributes, and skills leading to improvements in patients’ 
health and health outcomes.   
The category of printed materials has expanded to include electronic dissemination of 
clinical information and educational materials, which is an increasingly popular method of 
communicating and acquiring medical knowledge.  Print and electronic communications are 
popular channels due to their relatively low cost and ease of development.  Although there are 
set-up charges involved in electronic communications, dissemination costs are extremely low 
making it much more cost effective than printing and distributing educational materials by sales 
representatives or direct mail.  However, electronic communications pose added risks because it 
is easy for anyone to disseminate medical or clinical information, which, as noted above, can 
result in changes in clinical practice that harm patients. 
The Cochrane Collaborative reviewed studies using printed and electronic educational 
materials to determine their impact on clinical practice and patient health outcomes, and to 
determine whether any specific characteristics (content, format, etc.) increase the effectiveness of 
printed materials in influencing health care professionals (Giguère A. L.-K., 2012).  They 
reviewed 45 studies including 14 randomized clinical trials (RTCs) and 31 interrupted time series 
(ITS) analyses; all but one compared printed or electronically distributed materials to doing 
nothing.   
The formal review suggests printed and electronic materials result in very slight 
improvements in clinical practice; but they are, in general, poor vehicles for disseminating 
clinically important and potentially practice changing information (Dornbusch, 2006; Jamtvedt, 
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2006; Oxman, 1995; Roila, 2004).  Because of the lack of comparative trials, there is insufficient 
evidence to estimate the impact, if any on patient outcomes (Giguère A. L.-K., 2012; Oxman, 
1995).  There is, however, limited evidence that an article published in The New England Journal 
of Medicine can increase oncologists’ awareness of new treatment-related data (Green, 2007). 
Medical education meetings.  Conferences, lectures, teaching, and training sessions 
involving two or more health care professionals comprise the category of educational meetings 
(Grimshaw J. M., 2012; Reeves, 2009).  There are two types of meetings, those with an 
interactive component and didactic sessions; they used to improve collaboration and health 
outcomes.  Research indicates interactive education is more effective than didactic lectures at 
changing physicians’ knowledge and actions (Satterlee, 2008); in fact, didactic presentations, 
including traditional continuing medical education (CME) programs used commonly to impart 
new clinical information to practitioners, are generally ineffective.  Pairing didactic lectures with 
interactive sessions is as effective as interactive sessions alone, but is more costly than one either 
alone.  There have not been any placebo-controlled studies published assessing the impact of 
educational meetings.     
Evidence suggests presentation of phase III data from clinical trials of cancer therapies at 
major medical meetings, such as ASCO, can results in swift and unexpected change in 
oncologists’ prescribing behavior, as evidenced by the earlier example involving use of ABMT as 
an advanced breast cancer treatment.  Unfortunately, as that situation suggests, early adoption of 
oncology treatments based on incomplete or unpublished clinical trials—even though presented at 
a prestigious medical meeting--does not always lead to improvements in patient outcomes 
(Green, 2007).  Assumptions have been made that published or presented phase II clinical trial 
data would also influence physician behavior, but there is little evidence supporting this belief. 
Educational outreach.  Educational outreach visits, also known as academic detailing or 
educational detailing, involve a trained individual (“detailer”), subject matter expert, or local 
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opinion leader visiting a physician at their practice site to motivate the physician to change a 
specific practice-related behavior (O’Brien, 2008); occasionally, these visits involve feedback.  
Academic detailing has become popular during the past decade as a way for payers (government 
and private) to influence physicians to prescribe less costly treatments or use less costly 
interventions and technologies.  Educational visits can lead to small to moderate improvements in 
patient care albeit at a high cost for recruiting, training, and paying educators, in addition to the 
lost productivity of the physicians engaged in these meetings (O’Brien, 2008; Roila, 2004).  
Combining visits with other methods of influencing behavior listed in this section is more 
effective than visits alone (Satterlee, 2008).  Mason and colleagues found, despite high costs, 
academic detailing could be a cost effective method of changing physician behavior depending on 
the goal of the intervention (Mason, 2001).   
Although, there are many examples of how this type of intervention has motivated 
prolonged change in prescribing behavior among physician in other specialties, only limited 
research exists regarding the effectiveness of academic detailing in changing oncologists’ 
prescribing behaviors.  One study evaluated the ability of detailers to increase oncologists’ 
prescribing of anti-emetic medications used to prevent or treat nausea and vomiting in cancer 
patients undergoing chemotherapy in accordance with clinical practice guidelines.  There was a 
positive impact in patients undergoing treatment with a medium to high degree of emetogenicity 
(ability to induce vomiting) (Roila, 2004).  However, prescribing of anti-emetics for patients 
receiving chemotherapy with a lower potential of causing nausea and vomiting decreased in the 
study population while use was increasing among oncologists who had not received a visit.   
Despite evidence academic detailing can be effective, no one knows for sure the specific 
attributes of trainers, physicians, topics, and number of visits associated with effective 
interventions (O’Brien, 2008).  One thing is clear, it is unlikely educational outreach visits alone 
make a significant impact on clinical outcomes. 
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Opinion leaders.  Opinion leaders, also known as thought leaders, are physicians or other 
health care professionals considered by their peers to be likeable, trustworthy, knowledgeable, and 
influential (Flodgren G. P., 2011; Grimshaw J. M., 2012).  Opinion leadership depends on an 
individual’s ability to influence informally the attitudes or behaviors of others.  Respect is earned and 
maintained based on a person’s perceived technical competency and accessibility.  Likeability, while 
useful, is not an absolute requirement for effective thought leadership.  Thought leadership is usually 
a lever for positive change; however, opinion leaders who oppose change can emerge as a significant 
barrier even when there is compelling clinical evidence supporting the need for and benefits of 
change (Majumdar, 2007).   
The Cochrane Collaboration’s 2011 systematic review of literature on opinion leader 
influence included 18 studies across a range of physician specialties and diseases; the 
effectiveness rate of the various interventions studied ranged from a 15% decrease in compliance 
with published guidelines to a 72% compliance with desired behaviors (Flodgren, 2011).  Overall, 
the intervention groups had a 12% absolute improvement across studies in adherence to thought 
leader recommendations.  Three of the studies used a multidisciplinary team approach to 
promoting evidence-based change.  This approach showed even greater effect (18%), however, 
the design of these studies made it impossible to assess the impact of individual members of a 
team. 
Evidence suggests opinion leaders can successfully influence the behavior of their peers; in 
fact, it appears to be one of the most effective methods of motivating physicians to change clinical 
behavior although the results of studies indicate effectiveness may vary depending on the individuals 
involved and the behavior(s) targeted for change.  It comes as no surprise, therefore, that 
pharmaceutical companies, payers, health systems, and medical societies spend millions of dollars 
each year on thought leader identification, development, and training.  However, focusing on 
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individual opinion leaders rather than multidisciplinary teams and/or multi-faceted interventions may 
limit the effectiveness of these efforts.   
Audit and feedback.  Audit and feedback involves comparing an individual health care 
professional’s performance to standards of practice or clinical guidelines, and subsequently providing 
feedback on performance versus the standard (Ivers, 2012).  It is one of the most widely studied and 
popular quality improvement interventions; it is similar to performance planning and reviews done by 
organizations to align employee work with organizational objectives.  The goal of audit and feedback 
is motivating providers to adopt behaviors leading to increases in efficiency and/or improvements in 
quality of care and health outcomes.   
The Cochrane Collaboration recently published a systematic review of 140 studies assessing 
the impact of audit and feedback on the clinical performance of health care professionals; more than 
80% of the studies involved physicians practicing in outpatient settings.  Slightly more than one-
quarter of the studies assessed the impact of audit and feedback on prescribing behavior; a large 
majority of medication-related studies involved treatment of cardiovascular disease or diabetes.  None 
of the studies involved cancer treatment.  There was one published study involving oncologists, 
which was mentioned in the educational outreach section above (Roila, 2004).  In addition to 
educational outreach, the investigators evaluated the effectiveness of audit and feedback.  Neither 
approach had much impact on oncologists’ prescribing behaviors.  Effectiveness of this type of 
intervention hinges primarily on the attributes of the feedback element (Ivers, 2012; Jamtvedt, 2006; 
Roila, 2004).  Feedback can be provided in written form, verbally, or both.  It can be a one-time 
assessment or provided on an ongoing basis.  Feedback can be provided by a supervisor or colleague, 
a peer, or recognized opinion leader from outside the organization or practice.   
Audit and feedback can positively affect patient care (Grimshaw J. M., 2012; Ivers, 2012; 
Jamtvedt, 2006; Satterlee, 2008).  However, the affect size varies widely from study to study 
ranging from negative to very large depending on the attributes of the feedback component; 
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generally, improvements are small to moderate.  Attributes associated with positive results 
include poor pre-intervention performance; feedback given in writing and verbally by a 
supervisor or colleague multiple times over an extended period; and use of clear objectives and an 
action plan.  Some evidence suggests audit and feedback may be more effective when used in 
combination with other methods, such as reminders; however, results of studies are mixed (Ivers, 
2012; Jamtvedt, 2006).   
Reminders.  Reminders are used in health care settings for the same reason we use them 
in everyday life, except in this case they are tied to specific health care processes, medication 
prescribing, test ordering, or patient-physician encounters.  Often physicians do not base clinical 
decisions on best evidence because of information overload or process breakdowns (McDonald, 
1976).  The primary purpose of reminders is closing the gap between clinical guidelines or 
standards of care and usual care.  Reminders can effectively influence physician behaviors across 
a variety of clinical settings (Balas, 2000; Buntinx, 1993; Mandelblatt, 1995; Szilagyi, 2000; 
Wensing, 1994).  They can be verbal, written, or electronic, and can be embedded in electronic 
health records or e-prescribing systems to serve as point-of-service prompts.  Much of the 
research done in health care settings has involved computerized reminders because of the ease of 
implementation and data capture (Grimshaw J. M., 2012).   
There are four types of written reminders, including generic cue sheets (e.g. sticky notes) 
with no response required; check lists requiring a recorded response; patient profiles with patient-
specific information; and profile checklists also requiring a response be recorded (Pantoja, 2009).  
Paper reminders effectively enhance outcomes to a small to moderate degree.  Even though 
paper reminders are much less expensive and easier to implement than electronic reminders, they are 
easier to misplace, overlook or ignore. 
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A recent review of the effectiveness of electronic reminders in improving process and 
outcomes of care published by the Cochrane Collaboration evaluated the outcomes of 28 studies 
involving computerized reminders (Shojania, 2011).  The review was an update of a previous 
publication by the same authors in 2009 (Shojania, 2009).  Overall, computerized reminders have a 
small to moderate impact with the largest effect being process adherence at 4.2%, followed by 
vaccinations and test ordering (3.8%), and medication ordering (3.3%).  A small number of studies 
included in the review produced statistically significant improvements; they all involved the 
computerized order entry system at Brigham and Women’s Hospital.  Otherwise, no specific reminder 
attribute or context was significantly associated with the magnitude of the observed behavior change 
attributed to computer-generated reminders (Loo, 2011; Shojania, 2011).   
Financial incentives.  Payers and physicians have different goals.  Typically, payers seek to 
minimize health care costs while physicians are more interested in the health and quality of life of 
their patients (Holcombe, 2011).  It is assumed physicians can be motivated by money to change 
clinical behaviors ranging from stricter adherence to clinical practice guidelines to making evidence-
based treatment decisions to decreasing prescribing of expensive brand name medications.  However, 
published results for this method are mixed (Farina K. , 2012; Feinberg, 2012; Flodgren G. E., 2011; 
Scott, 2011).  The disparity in these study results is often attributed to the inherent conflict between 
extrinsic rewards and intrinsic physician motivators (Flodgren G. E., 2011); evidence suggests when 
intrinsic motivation is high, as it is in physicians, financial incentives may less effective in motivating 
behavior change.   
There are five basic categories of incentives: (1) limited duration contracts; (2) payment for 
each service, episode, or visit; (3) payment for providing care for a specific patient population, such 
as low-income single mothers; (4) adhering to pre-specified treatment or quality targets; and (5) 
mixed systems.  The second, third and fourth categories are generally effective in motivating change, 
although the affect is usually small; however, the same is not true of contracts or mixed systems.  
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Financial incentives are generally effective in improving processes of care, referrals, reducing 
hospital admissions, and lowering medication costs, and generally ineffective at improving adherence 
to clinical practice guidelines.   
The use of financial incentives by payers is increasing despite lack of convincing evidence 
they improve quality of care or health outcomes (Flodgren G. E., 2011; Scott, 2011).  There are a 
number of innovative performance-based payer programs, including some initiated by CMS, being 
implemented currently that are designed to improve quality of care, health outcomes, and adherence 
to clinical practice guidelines while reducing variations in care and costs.  Data generated from these 
interventions will enhance the understanding of the impact of financial incentives on physician 
behavior and quality of care.   
Summary 
Part one of chapter two outlines options available for treating advanced NSCLC, and the risks 
associated with making empiric treatment decisions based on clinical, tumor, or patient-specific 
characteristics instead of using the genetic profile of the tumor as a guide.  Opinion leaders in lung 
cancer treatment and guideline developers believe EGFR mutation testing helps oncologists make 
better informed and more precise treatment decisions.  However, most oncologists have not yet 
integrated EGFR testing into clinical practice and very little is known about why, in the face of strong 
evidence and expert recommendations they have been slow to integrate EGFR testing into their care 
of patients with advanced or metastatic NSCLC.   
Clearly, motivating physicians to change their clinical practice behaviors is no easy task.  
There are a myriad of factors influencing change--some positive and others negative.  Several factors 
were reviewed in the beginning of part two of chapter two; they are listed in the table below. 
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Table 6 - Factors Influencing Physicians' Clinical Behavior  
Facilitators of change Barriers to change 
 Federal legislation and regulations 
 Institute of Medicine 
 Lung Cancer Mutation Consortium 
and the Biomarkers Consortium 
 Patient advocacy organizations 
 Health care professional associations 
 Payers/MCOs 
 Clinical practice guidelines 
 
 Federal legislation and regulations 
 Payers/MCOs 
 Lack of motivation and time/clinical inertia 
 Information and work overload 
 Lack of knowledge or training in genetics 
 Lack of buy-in for need to change 
 Disagreement with proposed changes 
 Perceived threat to personal autonomy 
 Aversion to “cookbook” medicine 
 Fear of genetic discrimination against patients by 
employers and insurers 
 
There is no “magic bullet” for developing successful interventions aimed at motivating physicians 
to change their approach to diagnosing and treating specific diseases (Oxman, 1995).  Developing formal 
clinical practice guidelines is an important first step in creating a path and rationale for change.  However, 
motivating physicians to follow established guidelines remains a significant challenge.   
The Cochrane Collaboration has published a number of formal systematic reviews of published 
studies exploring the effectiveness of specific physician behavior-change interventions.  The interventions 
and their relative ability to motivate desired changes in physicians’ clinical behaviors are shown in the 
table below.  
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Table 7 - Interventions and Their Impact on Physicians' Clinical Practice Behavior  
Intervention category Magnitude of effect 
Printed education materials (passive dissemination) Small 
Medical education meetings 
Didactic lectures Small 
Interactive sessions Moderate 
Didactic and interactive combined (no better than interactive 
alone) 
 
Moderate 
Educational outreach Small to moderate 
Opinion leaders Large 
Audit and feedback Small to moderate 
Reminders (paper and electronic) Small to moderate 
Financial incentives 
Limited duration contracts No effect 
Payment for each service, episode, or visit Small 
Payment for providing care for a specific patient population Small 
Adhering to pre-specified treatment or quality targets Small 
Mixed systems No effect 
 
Use of guideline implementation strategies remains an inexact science even after 40 years of 
study (Grimshaw J. M., 2004; Lomas, 1989; Osarogiagbon, 2011; Roila, 2004; Satterlee, 2008; Wong 
R. K., 2012).  No single-pronged approach or combination of approaches works consistently and 
reliably to motivate changes in physician behaviors.  However, complex multi-faceted interventions 
combining several of the approaches listed above show promise.  Based on experience, it appears 
unlikely a universally successful single or multi-faceted approach will be identified anytime soon.   
The benefits of increasing use of EGFR testing when selecting from among available 
treatment options for patients with advanced or metastatic NSCLC are unmistakable and appear to be 
irrefutable.  Even so, adherence to EGFR testing recommendations remains much lower than might 
be expected after sustained efforts aimed at motivating oncologists to adopt testing as standard 
practice when caring for patients with lung cancer (Alt, 2011; Lynch J. A., 2013).  As noted in the 
beginning of part two of chapter two, there are a number of factors at work facilitating use of EGFR 
testing; however, the criteria oncologists consider when deciding whether to use an EGFR test for a 
specific patient and the implications they have for increasing the use of EGFR testing by oncologists 
remain a mystery.  
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Chapter three in this manuscript outlines a research study designed to begin uncovering those 
factors and influencers.  The insights and understanding gained from the literature review and key 
informant interviews with oncologists who treat patients with NSCLC will help inform the plan put 
forth in chapter five to motivate oncologists to increase their use of EGFR testing when treating 
patients with advanced or metastatic NSCLC.   
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APPENDIX B – INTERVIEW RECRUITMENT EMAIL 
Email subject line: UNC research opportunity for oncologists treating lung cancer 
Dear Dr. ((insert name)), 
In collaboration with the Lung Cancer Initiative of North Carolina, we invite you to 
participate in an important study about the factors you consider when deciding whether to perform an 
EGFR test when treating a patient with advanced or metastatic lung cancer.  My name is Patti Pozella 
and I am conducting a research study with oncologists who treat patients with lung cancer as a part of 
the requirements for a doctoral degree in Health Administration from the Gillings School of Global 
Public Health at UNC Chapel Hill.  This is an independent study with no outside funding.   
The study involves a brief telephone interview (between 20 to 30 minutes in length), 
scheduled at your convenience.  We will be discussing factors you consider when deciding whether to 
order a genetic test to identify the presence of specific mutations in the epidermal growth factor 
receptor (EGFR) gene in patients being treated for advanced or metastatic non-small cell lung cancer.  
Although the understanding of the genetic basis of lung cancer has grown tremendously in recent 
years, little is known about what influences the decisions oncologists make about EGFR mutation 
testing, which is why your participation in this project is so important.   
The interview will be recorded; however, use of a pseudonym during the interview will 
ensure your name is not associated with your responses.  In addition, the information gathered during 
the 18 to 20 interviews being conducted will be aggregated and presented as group data.  The file 
linking your name and contact information with your pseudonym will be encrypted and only I will 
know the password required to access the linking file.  Deductive disclosure, which is the discerning 
of an individual respondent's identity and responses based on known characteristics of that individual, 
is possible, but unlikely due to the number of interviews being conducted for this research project.  
You may terminate the interview at any point in the discussion. 
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I understand you are very busy and I promise to be respectful of your time.  If you are 
interested in participating, please respond affirmatively to this email and confirm that you treat 
patients with advanced or metastatic non-small cell lung cancer.  Please also provide contact 
information (name, phone number and email address) for the person I should contact to schedule your 
interview.     
Please feel free to email me at pozella@email.unc.edu if you have any questions about this 
research.    
A committee that works to protect your rights and welfare reviews all research on human 
volunteers.  If you have any questions or concerns regarding your rights as a research subject you 
may contact, anonymously if you wish, the Institutional Review Board for the University of North 
Carolina Chapel Hill at (919) 966-3113 or via email at IRB_subjects@unc.edu with study number # 
13-2569 (7-26-2013). 
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APPENDIX C – INTERVIEW RECRUITMENT TELEPHONE SCRIPT 
Hello Dr. ((insert name)), 
In collaboration with the Lung Cancer Initiative of North Carolina, we invite you to 
participate in an important study about the factors you consider when deciding whether to perform an 
EGFR test when treating a patient with advanced or metastatic lung cancer.  My name is Patti Pozella 
and I am conducting a research study with oncologists who treat patients with lung cancer as a part of 
the requirements for a doctoral degree in Health Administration from the Gillings School of Global 
Public Health at UNC Chapel Hill.  This is an independent study with no outside funding.   
I am hoping you will agree to participate in a brief telephone interview (between 20 to 30 
minutes in length).  We will schedule the interview at your convenience.  We will be discussing 
factors you consider when deciding whether to order a genetic test to identify the presence of specific 
mutations in the epidermal growth factor receptor (EGFR) gene in patients being treated for advanced 
or metastatic non-small cell lung cancer.  Although the understanding of the genetic basis of lung 
cancer has grown tremendously in recent years, little is known about what influences the decisions 
oncologists make about EGFR mutation testing, which is why your participation in this project is so 
important.   
The interview will be recorded; however, I will be using pseudonyms during the interview 
process, which will ensure your name is not associated with your responses.  I will also be 
aggregating the data across the 18 to 20 interviews I will be conducting and the data will be presented 
as group data.  The file linking your name and contact information with your pseudonym will be 
encrypted and only I will know the password required to access the linking file.   
It is possible, using deductive disclosure, which is the discerning of an individual 
respondent's identity and responses based on known characteristics of that individual, but unlikely 
someone will be able to identify your responses due to the number of interviews being conducted for 
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this research project.  You may terminate the interview at any point in the discussion.  I understand 
you are very busy and I promise to be respectful of your time.   
1. Are you willing to participate?   
 NO – terminate.  Thank you for taking the time to talk with me today.  Have a nice day. 
2. Can you please confirm that you treat patients with advanced or metastatic non-small cell 
lung cancer? 
NO – terminate.  Unfortunately, this research pertains to the treatment of lung cancer, so you 
are not eligible to participate, but I appreciate time you have spent talking with me today.    
3. Can we schedule the interview now? 
NO.  Who can I call to schedule a time for the interview (ask for name, email and phone 
number)? 
YES.  Schedule and ask for MD’s email address so a reminder can be sent. 
 Please feel free to call me at 919-607-4070 if you have questions or need to reschedule our 
interview.   
A committee that works to protect your rights and welfare reviews all research on human 
volunteers.  If you have any questions or concerns regarding your rights as a research subject you 
may contact, anonymously if you wish, the Institutional Review Board for the University of North 
Carolina Chapel Hill at (919) 966-3113 or via email at IRB_subjects@unc.edu with study number # 
13-2569 (7-26-2013).  
Thank you.  I am looking forward to talking with you again soon.  
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APPENDIX D – INTERVIEW GUIDE 
I. Introduction 
Hello.  I’d like to start by thanking you for talking with me today.  My name is Patti Pozella 
and I’ll be interviewing you.   I am a doctoral student at the UNC Chapel Hill Gillings School of 
Global Public Health and the interview we’re doing today is part of my dissertation, which is being 
done in partnership with the Lung Cancer Initiative of North Carolina.  This is an independent 
research project with no outside funding.   
We’ll be discussing the factors you consider when deciding whether to use a genetic test to 
identify patients with non-small cell lung cancer who have specific mutations in the epidermal growth 
factor receptor gene (EGFR testing) prior to making treatment decisions.  Your opinions, experiences, 
and observations are very valuable because little is known about what influences the decisions 
oncologists make about EGFR mutation testing.   
Your participation is very important.  I am interested in all of your ideas, comments, and 
suggestions.  Please feel free to share your thoughts, talk candidly and elaborate during the 
discussion.  We can revisit topics already discussed if you think of something you forgot to mention 
and would like to share. 
I will be recording our discussion because I want to make sure I do not miss anything you 
have said.  After the interviews are complete, I will carefully review and summarize the comments 
made by all of the oncologists participating in this research.  The information used in the dissertation 
manuscript will be aggregated and presented as group data.  You have my assurance that all of your 
comments will remain confidential and nothing you say will be connected with your name.  To ensure 
your confidentiality, I will not refer to you by name, nor should you mention your own name during 
the audio recording of this interview.  The file linking your name and contact information with your 
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assigned pseudonym has been encrypted and password protected.  I am the only one who knows the 
password required to access the linking file. 
Please confirm you are consenting to participate in this research study (wait for confirmation 
before proceeding). 
II. Specialty and practice-related questions 
1. I’d like to begin by asking whether you are a general or thoracic oncologist? 
2. About how many people with advanced or metastatic non-small cell lung cancer do 
you treat in an average month?   
2a.  How many of those patients are newly diagnosed? 
Probe, if necessary 
  It’s OK to estimate the number of people you treat if you don’t know for sure. 
3. Can you please tell me little bit about where you work, such as whether it is a 
hospital or community-based practice; number of locations served; whether the 
practice is associated with a health system, local hospital, etc.?  
Probe, if necessary 
Do you practice in a: 
a) Single location or multiple locations? 
b) Rural or more urban setting [or both]? 
c) Privately or publically owned facility? 
d) Academic or non-academic setting? 
e) Academic medical center, community hospital, community office-based practice 
or other type of setting? 
  
 116 
EGFR testing questions 
The next few questions focus on the factors you consider when deciding whether or not to 
order an EGFR test for a patient with advanced or metastatic non-small cell lung cancer. 
4. Thinking about the patients that you treat with advanced or metastatic non-small cell 
adenocarcinoma of the lung, do you NEVER, SOMETIMES OR ALWAYS order 
EGFR testing before treating them?   
IF ANSWER to Q. 4 is NEVER, SKIP to Q. 8 
5.  What percentage of your patients undergoes EGFR testing before starting treatment?  
IF ANSWER to Q. 4 IS SOMETIMES OR ALWAYS: 
6.  What are your main reasons for ordering EGFR mutation tests for your patients?   
Probe, if necessary 
a) Institutional or practice protocol  
b) Insurer or managed care requirement 
c) Clinical practice guideline recommendation 
d) Clinical evidence or published literature 
e) Standard of care 
f) Personal experience with testing 
g) Peer suggestion or recommendation 
h) Patient request 
i) Is there anything else you would like to mention? 
7.  Is there any one thing that stands out in your mind as a particularly compelling reason 
to test your patients? 
8.  What is the main reason or reasons you decide not to order an EGFR mutation test 
for a patient?   
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Probe, if necessary 
a) Test not available 
b) Patient not fit for biopsy 
c) Patient refuses 
d) Time it takes to get results 
e) Cost or patient can’t afford it 
f) Insurance (won’t pay for the test, require prior authorization) 
g) Clinical evidence or clinical practice guidelines 
h) Peer suggestion/recommendation 
9.   Is there any one thing that is the most compelling reason for not testing your patients? 
10.  Do you expect your future use of EGFR testing to increase, decrease, or stay the 
same?  
10a.  Why? 
IV. Closing 
Before we wrap up the interview, I would like to ask a couple of quick questions that will 
help me to better characterize survey participants when analyzing the results. 
11.  How many years have you been in practice since completing your oncology training?   
12. One last question…what percent of the patients you treat for lung cancer have 
advanced or metastatic non-small cell lung cancer?  _____% 
V. Thank you 
Thank you for participating in my research project and for the time you spent with me.    
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